<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tp="http://www.plazi.org/taxpub" article-type="review-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">89</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:CCBBD2E1-BDAF-5702-AE4B-0E4910A4C7D6</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Pharmacia</journal-title>
        <abbrev-journal-title xml:lang="en">PHAR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0428-0296</issn>
      <issn pub-type="epub">2603-557X</issn>
      <publisher>
        <publisher-name>Bulgarian Pharmaceutical Scientific Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/pharmacia.70.e109011</article-id>
      <article-id pub-id-type="publisher-id">109011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Pharmaceutics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>﻿Pharmacogenetic variants of <italic>CYP2C9</italic> and <italic>CYP2C19</italic> associated with adverse reactions induced by antiepileptic drugs used in Peru</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Alvarado</surname>
            <given-names>Angel T.</given-names>
          </name>
          <email xlink:type="simple">eaa.alvarado@hotmail.com</email>
          <uri content-type="orcid">https://orcid.org/0000-0001-8694-8924</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Muñoz</surname>
            <given-names>Ana María</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Varela</surname>
            <given-names>Nelson</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0002-5229-3007</uri>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Sullón-Dextre</surname>
            <given-names>Luis</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Pineda</surname>
            <given-names>Mario</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Bolarte-Arteaga</surname>
            <given-names>Mario</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Bendezú</surname>
            <given-names>María R.</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0002-3053-3057</uri>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>García</surname>
            <given-names>Jorge A.</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0001-9880-7344</uri>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Chávez</surname>
            <given-names>Haydee</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0002-8717-4307</uri>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Surco-Laos</surname>
            <given-names>Felipe</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-0805-5535</uri>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Melgar-Merino</surname>
            <given-names>Elizabeth J.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Cuba-Garcia</surname>
            <given-names>Pompeyo A.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Molina-Cabrera</surname>
            <given-names>Aura</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Pari-Olarte</surname>
            <given-names>Bertha</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Bonifaz-Hernandez</surname>
            <given-names>Mario</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Panay-Centeno</surname>
            <given-names>Juan F.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kong-Chirinos</surname>
            <given-names>José</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Almeida-Galindo</surname>
            <given-names>José</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line>International Research Unit in Molecular Pharmacology and Genomic Medicine (UNIPHARMAGEM), VRI, San Ignacio de Loyola University, Lima, Peru</addr-line>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line>Institute of Food Science and Nutrition, ICAN, San Ignacio de Loyola University, Lima, Peru</addr-line>
      </aff>
      <aff id="A3">
        <label>3</label>
        <addr-line>Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Faculty of Medicine, University of Chile, Santiago, Chile</addr-line>
      </aff>
      <aff id="A4">
        <label>4</label>
        <addr-line>Molecular Pharmacology Society of Peru, Lima, Peru</addr-line>
      </aff>
      <aff id="A5">
        <label>5</label>
        <addr-line>Pharmacy and Biochemistry, Faculty of Health Sciences, Scientific University of the South, UCSUR, Lima, Peru</addr-line>
      </aff>
      <aff id="A6">
        <label>6</label>
        <addr-line>Human Medicine, Continental University, Lima, Peru</addr-line>
      </aff>
      <aff id="A7">
        <label>7</label>
        <addr-line>Faculty of Pharmacy and Biochemistry, San Luis Gonzaga National University of Ica, Ica, Peru</addr-line>
      </aff>
      <aff id="A8">
        <label>8</label>
        <addr-line>Faculty of Human Medicine, San Luis Gonzaga National University of Ica, Ica, Peru</addr-line>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Angel T. Alvarado (<email xlink:type="simple">eaa.alvarado@hotmail.com</email>)</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>08</month>
        <year>2023</year>
      </pub-date>
      <volume>70</volume>
      <issue>3</issue>
      <fpage>603</fpage>
      <lpage>618</lpage>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/16DA8035-C80F-5721-BF33-685D19813A18">16DA8035-C80F-5721-BF33-685D19813A18</uri>
      <history>
        <date date-type="received">
          <day>04</day>
          <month>07</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>08</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Angel T. Alvarado, Ana María Muñoz, Nelson Varela, Luis Sullón-Dextre, Mario Pineda, Mario Bolarte-Arteaga, María R. Bendezú, Jorge A. García, Haydee Chávez, Felipe Surco-Laos, Elizabeth J. Melgar-Merino, Pompeyo A. Cuba-Garcia, Aura Molina-Cabrera, Bertha Pari-Olarte, Mario Bonifaz-Hernandez, Juan F. Panay-Centeno, José Kong-Chirinos, José Almeida-Galindo</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>﻿Abstract</label>
        <p>Epilepsy is the most common neurological disorder with a worldwide incidence of 20% and a treatment failure rate of 25–30%. The fluctuation in serum levels, efficacy and safety of antiepileptic drugs can be attributed to single nucleotide polymorphisms of genes encoding their respective proteins involved in drug metabolism. The present study attempted to evaluate the pharmacogenetic variants of <italic>CYP2C9</italic> and <italic>CYP2C19</italic> associated with adverse reactions induced by antiepileptic drugs used in Peru. Few studies were found to significantly associate the <italic>CYP2C9*2</italic>, <italic>CYP2C9*3</italic>, <italic>CYP2C19*2</italic>, and <italic>CYP2C19*3</italic> single nucleotide polymorphisms with elevated serum levels of valproic acid and carbamazepine, and valproic acid induction of hyperammonemia, and adverse reactions cutaneous for carbamazepine. There is further evidence of a significant association of <italic>CYP2C9*2/CYP2C9*3</italic> with severe cutaneous adverse reactions (<abbrev xlink:title="severe cutaneous adverse reactions" id="ABBRID0ERBAC">SCARs</abbrev>) such as Stevens-Johnson syndrome (<abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EVBAC">SJS</abbrev>) and epidermal necrolysis (<abbrev xlink:title="epidermal necrolysis" id="ABBRID0EZBAC">TEN</abbrev>) phenytoin-induced. <italic>CYP2C9*3</italic> may be a pharmacogenetic biomarker for such a drug. It is proposed to reduce the dose of drugs for intermediate and poor metabolizers. No pharmacogenetic studies were found in patients with epilepsy in Peruvian populations. It is concluded that this review could help physicians in the prediction and prevention of adverse reactions induced by antiepileptic drugs, as well as to improve their pharmacotherapeutic results. It could also be used as scientific evidence to carry out pharmacogenetic and precision medicine studies in Peruvian patients with epilepsy, due to their tricontinental and Latin American ancestry.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>Antiepileptic drugs</kwd>
        <kwd>
          <italic>CYP2C9</italic>
        </kwd>
        <kwd>
          <italic>CYP2C19</italic>
        </kwd>
        <kwd>pharmacogenetics</kwd>
        <kwd>precision medicine</kwd>
        <kwd>clinical implication</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="SECID0EOCAC">
        <title>Citation</title>
        <p>Alvarado AT, Muñoz AM, Varela N, Sullón-Dextre L, Pineda M, Bolarte-Arteaga M, Bendezú MR, García JA, Chávez H, Surco-Laos F, Melgar-Merino EJ, Cuba-Garcia PA, Molina-Cabrera A, Pari-Olarte B, Bonifaz-Hernandez M, Panay-Centeno JF, Kong-Chirinos J, Almeida-Galindo J (2023) Pharmacogenetic variants of <italic>CYP2C9</italic> and <italic>CYP2C19</italic> associated with adverse reactions induced by antiepileptic drugs used in Peru. Pharmacia 70(3): 603–618. <ext-link xlink:href="10.3897/pharmacia.70.e109011" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3897/pharmacia.70.e109011</ext-link></p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="﻿Introduction" id="SECID0E4CAC">
      <title>﻿Introduction</title>
      <p>Epilepsy is a chronic neurological disorder characterized by self-limited seizures with a high probability of recurrence within the next 10 years, which may have a genetic, acquired or idiopathic origin (<xref ref-type="bibr" rid="B32">Fisher et al. 2017</xref>; <xref ref-type="bibr" rid="B91">Thong et al. 2020</xref>; <xref ref-type="bibr" rid="B7">Alvarado et al. 2022a</xref>); being the second most frequent neurological condition worldwide, and according to the World Health Organization (<abbrev xlink:title="World Health Organization" id="ABBRID0EPDAC">WHO</abbrev>), there are some 50 million people with epilepsy worldwide; and of these, 90% are registered in developing countries, while in countries with developed economies between 40–70 new cases/day and per 100,000 people are diagnosed (<xref ref-type="bibr" rid="B66">Moshe et al. 2015</xref>; <xref ref-type="bibr" rid="B17">Burneo et al. 2017</xref>). In Peru it is estimated that the prevalence of epilepsy is 11.9–32.1 per 1000 people, which is why it is currently a national and global public health problem (<xref ref-type="bibr" rid="B18">Burneo et al. 2005</xref>; <xref ref-type="bibr" rid="B17">Burneo et al. 2017</xref>). In Peru, antiepileptic drugs (<abbrev xlink:title="antiepileptic drugs" id="ABBRID0EDEAC">AEDs</abbrev>) approved in the Single National Petition for Essential Medicines are used to treat this disease, including valproic acid (<abbrev xlink:title="valproic acid" id="ABBRID0EHEAC">VPA</abbrev>), carbamazepine (<abbrev xlink:title="carbamazepine" id="ABBRID0ELEAC">CBZ</abbrev>) and phenytoin (<abbrev xlink:title="phenytoin" id="ABBRID0EPEAC">PHT</abbrev>). Most patients with epilepsy respond to standard treatment, however, between 25–30% present resistance (<xref ref-type="bibr" rid="B78">Sillanpaa and Schmidt 2006</xref>; <xref ref-type="bibr" rid="B80">Sisodiya and Marini 2009</xref>; <xref ref-type="bibr" rid="B52">Kwan et al. 2010</xref>), and in these cases epilepsy surgery is used as an alternative treatment, without considering the polymorphisms in the <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genes of each patient, the same ones that are responsible for the metabolic phenotypes involved in the variability of the response and in the adverse reactions due to the high serum level of antiepileptic drugs (<xref ref-type="bibr" rid="B82">Smolarz et al. 2021</xref>; <xref ref-type="bibr" rid="B60">Maqbool et al. 2022</xref>). The <italic>CYP2C9</italic> gene is highly polymorphic, with <italic>CYP2C9*1</italic> being the wild type allele, <italic>CYP2C9*2</italic> (rs1799853, c.430C&gt;T) and <italic>CYP2C9*3</italic> (rs1057910, c.1075A&gt;C) encoding proteins of reduced function (<xref ref-type="bibr" rid="B22">Chaudhry et al. 2010</xref>; <xref ref-type="bibr" rid="B72">Saldaña-Cruz et al. 2013</xref>; <xref ref-type="bibr" rid="B20">Céspedes-Garro et al. 2015</xref>; <xref ref-type="bibr" rid="B28">Claudio-Campos et al. 2017</xref>; <xref ref-type="bibr" rid="B3">Alvarado et al. 2019</xref>); while the <italic>CYP2C19</italic> gene presents more than 35 allelic variants (<xref ref-type="bibr" rid="B99">Yin and Miyata 2011</xref>), of which <italic>CYP2C19*1</italic> the wild type allele, <italic>CYP2C19*2</italic> (c.681G&gt;A) and <italic>CYP2C19*3</italic> (636G&gt;A) encode non-functional proteins (<xref ref-type="bibr" rid="B79">Sim et al. 2006</xref>; <xref ref-type="bibr" rid="B14">Beitelshees et al. 2011</xref>; <xref ref-type="bibr" rid="B71">Saeed and Mayet 2013</xref>; <xref ref-type="bibr" rid="B73">Scott et al. 2013</xref>; <xref ref-type="bibr" rid="B30">Dehbozorgi et al. 2018</xref>; <xref ref-type="bibr" rid="B61">Maruf et al. 2019</xref>; <xref ref-type="bibr" rid="B93">Vargas and Cobar 2021</xref>); <italic>CYP2C19*17</italic> (g. -806 C&gt;T) encodes proteins with greater metabolic function (<xref ref-type="bibr" rid="B41">Hamdy et al. 2002</xref>; <xref ref-type="bibr" rid="B53">Lee 2013</xref>; <xref ref-type="bibr" rid="B81">Skadrić and Stojković 2020</xref>). <italic>CYP2C9*2</italic> and <italic>CYP2C9*3</italic> single nucleotide polymorphisms have been reported to be significantly associated with reduced metabolism and elevated serum level of phenytoin inducing adverse reactions compared to wild-type subjects (<italic>CYP2C9*1</italic> and <italic>CYP2C19*1</italic>) (<xref ref-type="bibr" rid="B16">Brandolese et al. 2001</xref>; <xref ref-type="bibr" rid="B58">López-García et al. 2017</xref>; <xref ref-type="bibr" rid="B54">Liao et al. 2018</xref>); <italic>CYP2C19*2</italic> and <italic>CYP2C19*3</italic> are also associated with reduced metabolism (<xref ref-type="bibr" rid="B59">Makowska et al. 2021</xref>; <xref ref-type="bibr" rid="B36">Garg et al. 2022</xref>). <italic>CYP2C9*3</italic> carriers require 37% less dose of phenytoin to achieve therapeutic serum levels compared to the dose of <italic>CYP2C9*1</italic> carrier patients (<xref ref-type="bibr" rid="B92">van der Weide et al. 2001</xref>). <italic>CYP2C9*3</italic> is significantly associated with the occurrence of <abbrev xlink:title="phenytoin" id="ABBRID0EHJAC">PHT</abbrev>-induced gingival hyperplasia in Indian (<xref ref-type="bibr" rid="B36">Garg et al. 2022</xref>) and Japanese patients (<xref ref-type="bibr" rid="B45">Hirota et al. 2013</xref>). <italic>CYP2C19*2</italic> and <italic>CYP2C19*3</italic> predict the poor metabolizer (<abbrev xlink:title="poor metabolizer" id="ABBRID0EXJAC">PM</abbrev>) phenotype and in this group of patients an increase in the values of the area under the curve (<abbrev xlink:title="area under the curve" id="ABBRID0E2JAC">AUC</abbrev>) and the maximum plasmatic concentration (C<sub>max</sub>) of phenytoin is observed (<xref ref-type="bibr" rid="B45">Hirota et al. 2013</xref>). <italic>CYP2C9*2</italic>, <italic>CYP2C9*3</italic>, and <italic>CYP2C19*2</italic> have also been reported to be significantly associated with resistance to antiepileptic drugs (<xref ref-type="bibr" rid="B75">Seven et al. 2014</xref>).</p>
      <p>Due to these considerations, the PubMed-Medline database on pharmacogenomic studies and precision medicine in Peru has been reviewed, with these investigations being scarce in patients with epilepsy, therefore, a review study is warranted in accordance with the new treatment approach that is postulated through precision medicine in epilepsy, which considers the pharmacogenetic profile, the serum level of the drug, ethnicity, miscegenation, and the patient’s sex, to individualize the dose of the drug, which will allow maintaining serum levels within the therapeutic index and minimize the adverse reactions induced by antiepileptic drugs (Alvarado et al. 2021; <xref ref-type="bibr" rid="B7">Alvarado et al. 2022a</xref>, <xref ref-type="bibr" rid="B8">b</xref>, <xref ref-type="bibr" rid="B9">c</xref>; <xref ref-type="bibr" rid="B11">Alvarado et al. 2023</xref>). In this sense, we have addressed 4 questions that support this article: ¿What is the current status and knowledge of the subject? Worldwide, there is evidence that <italic>CYP2C9/CYP2C19</italic> single nucleotide polymorphisms (<abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EDLAC">SNPs</abbrev>) are associated with an increased risk of AED-induced adverse reactions; being these studies very limited or scarce in Peru; ¿What central question did this study address? By reviewing the scientific literature, an attempt has been made to find evidence of an association between the <italic>CYP2C9/CYP2C19</italic><abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EJLAC">SNPs</abbrev> and the adverse reactions induced by the <abbrev xlink:title="antiepileptic drugs" id="ABBRID0ENLAC">AEDs</abbrev> most widely used in Peru; ¿What does this study contribute to new knowledge? This review aims to inform medical specialists that patients with diplotypes predictive of intermediate and poor metabolizers who are treated with <abbrev xlink:title="antiepileptic drugs" id="ABBRID0ERLAC">AEDs</abbrev> are more likely to experience adverse reactions than are normal metabolizers; ¿How can this change pharmacogenetics and precision medicine? Knowing that the <italic>CYP2C9/CYP2C19</italic><abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EXLAC">SNPs</abbrev> influence drug response, and that pharmacogenetic tests should be performed prior to treatment, will make it possible to individualize the patient’s dose, which will ensure drug serum levels within the therapeutic index and, at the same time, minimize the AED-induced adverse reactions. In addition, this review will serve to generate scientific evidence, which will encourage analytical observational studies (cases/controls and cohorts) and randomized clinical trials (<abbrev xlink:title="randomized clinical trials" id="ABBRID0E2LAC">RCTs</abbrev>), and this will promote the implementation of precision medicine in health systems of Peru. The objective was to review the available evidence on the pharmacogenetic variants of <italic>CYP2C9</italic> and <italic>CYP2C19</italic> associated with adverse reactions induced by antiepileptic drugs used in Peru and their clinical impact on medicine.</p>
    </sec>
    <sec sec-type="﻿Search strategy and selection criteria" id="SECID0EDMAC">
      <title>﻿Search strategy and selection criteria</title>
      <p>A descriptive review of articles published in PubMed/Medline and Google Scholar was carried out. The search strategy was carried out using the keywords: “<italic>CYP2C9</italic> gene”; “<italic>CYP2C19</italic> gene”; “<italic>CYP2C9/C19</italic> SNP”; “<italic>CYP2C9/C19</italic> mutation” “pharmacokinetics of antiepileptic drugs”; “pharmacokinetics of valproic acid”; “pharmacokinetics of carbamazepine”; “Pharmacokinetics of Phenytoin”. Additionally, the Boolean operators AND, OR, and NOT were used to incorporate the use of <italic>CYP2C9/19</italic> genes and resistance, <italic>CYP2C9/19</italic> genes and adverse reactions, <italic>CYP2C9/C19</italic> enzymes that metabolize antiepileptic drugs, <italic>CYP2C9/19</italic> genes and clinical implication, which allowed a more refined review. No ethnic or language restriction was applied for the search and inclusion of published articles.</p>
    </sec>
    <sec sec-type="﻿Pharmacokinetics of antiepileptic drugs" id="SECID0EZMAC">
      <title>﻿Pharmacokinetics of antiepileptic drugs</title>
      <sec sec-type="﻿Pharmacokinetics of valproic acid" id="SECID0E4MAC">
        <title>﻿Pharmacokinetics of valproic acid</title>
        <p>Valproic acid (<abbrev xlink:title="Valproic acid" id="ABBRID0EDNAC">VPA</abbrev>) is a short-chain branched-chain fatty acid derivative, chemically named 2-propylpentanoic acid (<xref ref-type="bibr" rid="B31">Doré et al. 2017</xref>; <xref ref-type="bibr" rid="B94">Wallenburg et al. 2017</xref>; <xref ref-type="bibr" rid="B55">Li et al. 2021</xref>). Due to the pKa of 4.8, it is absorbed through the gastrointestinal mucosa to obtain a bioavailability &gt;95%, and a maximum plasma concentration (C<sub>max</sub>) of 23.5–25.3 mg/L, in a maximum time (t<sub>max</sub>) of 1.5 hours and an area under the curve (<abbrev xlink:title="area under the curve" id="ABBRID0EXNAC">AUC</abbrev><sup>o-∞</sup>) of 626–831 mg.h/L (<xref ref-type="bibr" rid="B9">Alvarado et al. 2022c</xref>). It has a narrow therapeutic index, therefore its serum level should be monitored during the course of therapy so that the drug exceeds the trough effective concentration (C<sub>mE</sub>) of 50 mg/L (350 mM) and does not exceed the trough toxic concentration (C<sub>MT</sub>) of 100 mg/L (700 mM) (<xref ref-type="bibr" rid="B21">Chadwick 1985</xref>; <xref ref-type="bibr" rid="B31">Doré et al. 2017</xref>; <xref ref-type="bibr" rid="B9">Alvarado et al. 2022c</xref>). After its absorption, it circulates through the blood bound to plasmatic proteins by 90%, mainly to albumin. Said binding is saturable, 93% at 50 mg/L, and 70% at 150 mg/L (<xref ref-type="bibr" rid="B38">Ghodke-Puranik et al. 2013</xref>; <xref ref-type="bibr" rid="B31">Doré et al. 2017</xref>); the free fraction of the drug (7%) crosses the blood-brain barrier, more than 30% of the free fraction of <abbrev xlink:title="valproic acid" id="ABBRID0EYOAC">VPA</abbrev> can cause adverse effects (<xref ref-type="bibr" rid="B94">Wallenburg et al. 2017</xref>). Steady state (C<sub>ss</sub>) is reached in 3 to 50 days, volume of distribution (Vd) is 0.1–0.4 L/kg in adults, 0.20–0.30 L/kg in children, half-life (t<sub>1/2</sub>) it is 4–20 h, the same time that decreases due to the action of enzyme-inducing drugs (<xref ref-type="bibr" rid="B9">Alvarado et al. 2022c</xref>). 40% of the <abbrev xlink:title="valproic acid" id="ABBRID0EIPAC">VPA</abbrev> dose is metabolized by phase I oxidation: CYP2C9, CYP2C19, CYP2A6 and CYP2B6 isoenzymes form 4-hydroxy valproic acid and 4-ene-<abbrev xlink:title="valproic acid" id="ABBRID0EMPAC">VPA</abbrev> implicated in hepatotoxicity (<xref ref-type="bibr" rid="B47">Jiang et al. 2009</xref>; <xref ref-type="bibr" rid="B38">Ghodke-Puranik et al. 2013</xref>; <xref ref-type="bibr" rid="B13">Bartra et al. 2021</xref>; <xref ref-type="bibr" rid="B9">Alvarado et al. 2022c</xref>); while CYP2A6 generates 3-hydroxy valproic acid, and through the action of CYP2C9, CYP2A6 and CYP2B6, <abbrev xlink:title="valproic acid" id="ABBRID0EBAAE">VPA</abbrev> is biotransformed into 5-hydroxy valproic acid (<xref ref-type="bibr" rid="B38">Ghodke-Puranik et al. 2013</xref>; <xref ref-type="bibr" rid="B9">Alvarado et al. 2022c</xref>; <xref ref-type="bibr" rid="B83">Song et al. 2022</xref>). Between 30–50% of valproic acid is metabolized by phase II conjugation, mainly by UDP-glucuronosyl transferase 2B7 (UGT2B7) and others (UGT1A3, A4, A6, A8, A9, A10; UGT2B15) that transfer the glucuronic acid group from UDP-α-D-glucuronic acid (<abbrev xlink:title="UDP-α-D-glucuronic acid" id="ABBRID0ERAAE">UDPGA</abbrev>) to the carboxylic group of <abbrev xlink:title="valproic acid" id="ABBRID0EVAAE">VPA</abbrev> to form valproyl 1-O-β-acyl glucuronide; metabolism is saturable, and metabolites are eliminated in the urine (<xref ref-type="bibr" rid="B48">Jin et al. 1993</xref>; <xref ref-type="bibr" rid="B84">Staines et al. 2004</xref>; <xref ref-type="bibr" rid="B38">Ghodke-Puranik et al. 2013</xref>; <xref ref-type="bibr" rid="B31">Doré et al. 2017</xref>; <xref ref-type="bibr" rid="B83">Song et al. 2022</xref>). UGT2B7*<italic>2</italic> may be involved in the increased area under the curve of serum <abbrev xlink:title="valproic acid" id="ABBRID0EPBAE">VPA</abbrev> concentrations (<xref ref-type="bibr" rid="B27">Chung et al. 2008</xref>). Fig. <xref ref-type="fig" rid="F1">1</xref> summarizes the metabolic pathway of valproic acid.</p>
        <fig id="F1" position="float" orientation="portrait">
          <object-id content-type="doi">10.3897/pharmacia.70.e109011.figure1</object-id>
          <object-id content-type="arpha">F1C45E03-5652-5F4A-8195-013EC10EBC4E</object-id>
          <label>Figure 1.</label>
          <caption>
            <p>Metabolism of valproic acid by phase I and II.</p>
          </caption>
          <graphic xlink:href="pharmacia-70-e109011-g001.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_892755.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/892755</uri>
          </graphic>
        </fig>
        <p>It is observed that valproic acid is metabolized by phase II conjugation with the participation of UGT1B7 and others (UGT1A3, UGT1A4 and UGT1B15) forming valproyl 1-O-β-acyl glucuronide. By phase I, valproic acid is oxidized into three main metabolites: by CYP2C19 and CYP2C9 (and with CYP2A6 and CYP2B6) valproic acid is converted to 4-hydroxy valproic acid; by action of CYP2A6 it is biotransformed into 3-hydroxy valproic acid; by the action of CYP2C9, CYP2A6 and CYP2B6 it is converted to 5-hydroxy valproic acid. Figure made by the authors.</p>
      </sec>
      <sec sec-type="﻿Pharmacokinetics of carbamazepine" id="SECID0EICAE">
        <title>﻿Pharmacokinetics of carbamazepine</title>
        <p>Carbamazepine (<abbrev xlink:title="Carbamazepine" id="ABBRID0EOCAE">CBZ</abbrev>: 5-H-dibenzazepine-5-carboxamide) is an iminostilbene-type antiepileptic (<xref ref-type="bibr" rid="B8">Alvarado et al. 2022b</xref>; <xref ref-type="bibr" rid="B25">Chbili et al. 2017</xref>), whose N of the dibenzazepine ring gives it a pKa of 2.3 and the free NH<sub>2</sub> group of the carboxamide generates the pKa 13.9; being a class 2 drug with low solubility and high permeability according to the Biopharmaceutical Classification System (<abbrev xlink:title="Biopharmaceutical Classification System" id="ABBRID0E3CAE">BCS</abbrev>) (<xref ref-type="bibr" rid="B5">Alvarado et al. 2021b</xref>, <xref ref-type="bibr" rid="B6">c</xref>), therefore it is absorbed by simple diffusion through the gastrointestinal mucosa (<xref ref-type="bibr" rid="B8">Alvarado et al. 2022b</xref>). Its bioavailability is 70–85%, establishing a minimum effective plasma concentration (C<sub>mE</sub>) of 4 mg/L and a minimum toxic concentration (C<sub>MT</sub>) of 12 mg/L as the optimal interval (<xref ref-type="bibr" rid="B25">Chbili et al. 2017</xref>; <xref ref-type="bibr" rid="B49">Johannessen Landmark et al. 2020</xref>; <xref ref-type="bibr" rid="B8">Alvarado et al. 2022b</xref>); the maximum time (t<sub>max</sub>) is 4–8 h, and the steady-state serum concentration (C<sub>ss</sub>) is reached in 28 days. Its binding to plasma proteins is high (UP 75–85%), and its volume of distribution (Vd) is 1.4 L/kg (<xref ref-type="bibr" rid="B2">Aldaz et al. 2011</xref>). By phase I carbamazepine is oxidized into three metabolites: by action of CYP3A4 it is converted to 2,3-carbamazepine epoxide; 3-hydroxy carbamazepine is formed by CYP3A4, CYP2B6 and CYP3A7; by the action of CYP2C19, CYP2C9 and other isoenzymes (CYP2C9, CYP3A4, CYP3A5, CYP1A2, CYP1A1, CYP2A6, CYP2C8 and CYP2D6) it is biotransformed into the main metabolite carbamazepine 10,11-epoxide (Lopez-Garcia et al. 2014; <xref ref-type="bibr" rid="B29">Darwish et al. 2015</xref>; <xref ref-type="bibr" rid="B39">Gierbolini et al. 2016</xref>). Carbamazepine 10,11-epoxide undergoes two biotransformation processes: by action of UGT2B7, UGT1A6 carbamazepine 10,11-epoxide N-β-glucuronide is generated; the second reaction is by action of epoxide hydrolase forming 10,11-dihydro-10,11-trans-dihydroxycarbamazepine (diOH-<abbrev xlink:title="carbamazepine" id="ABBRID0EMEAE">CBZ</abbrev>) (<xref ref-type="bibr" rid="B29">Darwish et al. 2015</xref>; <xref ref-type="bibr" rid="B25">Chbili et al. 2017</xref>); then UDP-glucuronosyl transferase 2B7, A6 and 2B (UGT2B7, UGT1A6 and UBG2B) is involved in the transfer of the glucuronic group of UDP-α-D-glucuronic acid (<abbrev xlink:title="UDP-α-D-glucuronic acid" id="ABBRID0EYEAE">UDPGA</abbrev>) to the diOH-<abbrev xlink:title="carbamazepine" id="ABBRID0E3EAE">CBZ</abbrev> metabolite to generate O-β-glucuronide of carbamazepine (<xref ref-type="bibr" rid="B29">Darwish et al. 2015</xref>; Alvarado et al. 2022). Chronic use of carbamazepine can induce its own metabolism, inducing UGT2B7, epoxide hydrolase, CYP3A4 (<xref ref-type="bibr" rid="B39">Gierbolini et al. 2016</xref>), CYP2C9, CYP2C19, and CYP1A2 (<xref ref-type="bibr" rid="B43">Hernández and Marín 2017</xref>). The half-life time (t<sub>1/2</sub>) in newborns is 12–64 hours, in children 10–13 hours and 8–20 hours in adults (<xref ref-type="bibr" rid="B2">Aldaz et al. 2011</xref>; <xref ref-type="bibr" rid="B49">Johannessen Landmark et al. 2020</xref>). Fig. <xref ref-type="fig" rid="F2">2</xref> shows the metabolism of carbamazepine by phase I and II.</p>
        <fig id="F2" position="float" orientation="portrait">
          <object-id content-type="doi">10.3897/pharmacia.70.e109011.figure2</object-id>
          <object-id content-type="arpha">9D378406-801E-52C9-963D-A7874660A37A</object-id>
          <label>Figure 2.</label>
          <caption>
            <p>Metabolism of carbamazepine by phase I and II.</p>
          </caption>
          <graphic xlink:href="pharmacia-70-e109011-g002.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_892756.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/892756</uri>
          </graphic>
        </fig>
        <p>It is observed that carbamazepine is metabolized by three main routes: by action of CYP3A4 it is converted into 2,3-carbamazepine epoxide; by CYP3A4, CYP3A7 and CYP2B6 it is converted to 3-hydroxy-carbamazepine. By the action of CYP2C19, CYP2C9 and others (CYP3A4, CYP1A1 and CYP2D6) carbamazepine is biotransformed into carbamazepine 10,11-epoxide. The metabolite carbamazepine 10,11-epoxide is biotransformed by two routes: directly to carbamazepine 10,11-epoxide N-β-glucuronide by action of UGT2B7 and UGT1A6; By action of epoxide hydrolase, 10,11-dihydro-10,11-trans-dihydroxycarbamazepine (diOH-<abbrev xlink:title="carbamazepine" id="ABBRID0EIGAE">CBZ</abbrev>) is generated, then this metabolite is conjugated by UGT2B7 forming O-β-glucuronide of carbamazepine. Figure made by the authors.</p>
      </sec>
      <sec sec-type="﻿Pharmacokinetics of phenytoin" id="SECID0EMGAE">
        <title>﻿Pharmacokinetics of phenytoin</title>
        <p>Phenytoin (<abbrev xlink:title="phenytoin" id="ABBRID0ESGAE">PHT</abbrev>) is a derivative of hydantoin (5,5-diphenylimidazolidine-2,4-dione) with a pKa of 8.3;2,59,60 being class 2 (low solubility and high permeability) according to the Biopharmaceutical Classification System (<abbrev xlink:title="Biopharmaceutical Classification System" id="ABBRID0EWGAE">BCS</abbrev>) (<xref ref-type="bibr" rid="B10">Alvarado et al. 2020</xref>), so it is absorbed in its non-ionized form through the gastrointestinal mucosa, generating a bioavailability of 80% (<xref ref-type="bibr" rid="B62">Milosheska et al. 2015</xref>; <xref ref-type="bibr" rid="B40">Guk et al. 2019</xref>; <xref ref-type="bibr" rid="B7">Alvarado et al. 2022a</xref>). It is another antiepileptic drug with a narrow therapeutic index, whose minimum effective plasma concentration (C<sub>mE</sub>) is 10 mg/L and the minimum toxic concentration (C<sub>MT</sub>) is 20 mg/L (<xref ref-type="bibr" rid="B90">Thaker et al. 2017</xref>). Phenytoin is metabolized by phase I oxidation, forming an intermediate metabolite 3’,4’-epoxide of phenytoin by the action of the CYP2C9 isoenzymes (90%) and by CYP2C19 (10%); then said metabolite undergoes two metabolic processes: by action of epoxide hydrolase, 3’,4’-dihydrodiol phenytoin is generated; and by action of CYP2C9 and CYP2C19 the main metabolite called 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) is generated. p-HPPH undergoes two metabolic processes: by action of CYP2C19 and to a lesser extent by CYP2C9, 3’,4’-dihydrodiol phenytoin is generated; and by phase II conjugation, UDP-glucuronosyl transferase 1A (UGT1A) is involved in the transfer of the glucuronic group of UDP-α-D-glucuronic acid (<abbrev xlink:title="UDP-α-D-glucuronic acid" id="ABBRID0ESHAE">UDPGA</abbrev>) to the p-HPPH metabolite to generate phenytoin O-β-glucuronide (Lopez-Garcia et al. 2014; <xref ref-type="bibr" rid="B12">Balestrini and Sisodiya 2018</xref>). Fig. <xref ref-type="fig" rid="F3">3</xref> summarizes the metabolic process of phenytoin.</p>
        <fig id="F3" position="float" orientation="portrait">
          <object-id content-type="doi">10.3897/pharmacia.70.e109011.figure3</object-id>
          <object-id content-type="arpha">A6A43298-5F65-5D52-9688-1A95505E4634</object-id>
          <label>Figure 3.</label>
          <caption>
            <p>Metabolism of phenytoin by phase I and II.</p>
          </caption>
          <graphic xlink:href="pharmacia-70-e109011-g003.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_892757.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/892757</uri>
          </graphic>
        </fig>
        <p>It is observed that phenytoin is metabolized by the action of CYP2C9 and CYP2C19 into phenytoin 3’,4’-epoxide, and by the action of epoxide reductase phenytoin is regenerated. The metabolite phenytoin 3´,4´-epoxide is metabolized by two routes: by action of epoxide hydrolase it becomes 3´,4´-dihydrodiol phenytoin; by the action of CYP2C9 and CYP2C19 it is converted to 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH); then p-HPPH is converted to 3´,4´-dihydrodiol phenytoin by the action of CYP2C9 and CYP2C19; at the same time p-HPPH by action of UGT1A is converted into O-β-glucuronide of phenytoin. Figure made by the authors.</p>
      </sec>
    </sec>
    <sec sec-type="﻿CYP2C9 and CYP2C19 genes related to the metabolism of antiepileptic drugs" id="SECID0ELIAE">
      <title>﻿<italic>CYP2C9</italic> and <italic>CYP2C19</italic> genes related to the metabolism of antiepileptic drugs</title>
      <sec sec-type="﻿CYP2C9 gene" id="SECID0EUIAE">
        <title>﻿<italic>CYP2C9</italic> gene</title>
        <p>The <italic>CYP2C9</italic> gene is located on the long arm of chromosome 10 in region 24 of 500 kb (10q24) consists of 9 exons and is highly polymorphic with more than 61 allelic variants and multiple sub-alleles (<xref ref-type="bibr" rid="B95">Wang et al. 2004</xref>; <xref ref-type="bibr" rid="B45">Hirota et al. 2013</xref>; <xref ref-type="bibr" rid="B67">Mukai et al. 2017</xref>; <xref ref-type="bibr" rid="B3">Alvarado et al. 2019</xref>; <xref ref-type="bibr" rid="B51">Karnes et al. 2021</xref>). Of clinical interest is the wild type <italic>CYP2C9*1</italic> allele that encodes a protein with 100% enzymatic function and whose diplotypes predict normal metabolizers (<abbrev xlink:title="normal metabolizers" id="ABBRID0EVJAE">NM</abbrev>) (<xref ref-type="bibr" rid="B19">Caudle et al. 2014</xref>; <xref ref-type="bibr" rid="B12">Balestrini and Sisodiya 2018</xref>); while the allelic variant <italic>CYP2C9*2</italic> CT (rs1799853, 430C&gt;T) consists of three alleles <italic>CYP2C9*2A</italic>, *<italic>2B</italic> and *<italic>2C34</italic> characterized by a one nucleotide transition from cytosine (C) to thymine (T) in position 430 (c.430C&gt;T) in exon 3 that results in the replacement of arginine (Arg) by cysteine (Cys) at position 144 of the protein (Arg144Cys) that has less interaction with its cofactor and whose function it is 12–50% compared to the wild type (<xref ref-type="bibr" rid="B22">Chaudhry et al. 2010</xref>; <xref ref-type="bibr" rid="B3">Alvarado et al. 2019</xref>; <xref ref-type="bibr" rid="B36">Garg et al. 2022</xref>). The allelic variant <italic>CYP2C9*3</italic> AC (rs1057910) is generated by a transversion of adenine (A) to cytosine (C) at base pair 1075 (c.1075A&gt;C) in exon 7, causing an isoleucine (Ile) change to leucine (Leu) in codon 359 (Ile359Leu) of the protein, varying the binding site for the drug and whose function is 5% compared to the wild type (<xref ref-type="bibr" rid="B22">Chaudhry et al. 2010</xref>; <xref ref-type="bibr" rid="B36">Garg et al. 2022</xref>); <italic>CYP2C9*5</italic> (Ile359Thr) and *6 (c. delA818) that predict poor metabolizers (<abbrev xlink:title="poor metabolizer" id="ABBRID0EBLAE">PM</abbrev>) (<xref ref-type="bibr" rid="B33">Fricke-Galindo et al. 2018</xref>). It has been established that an individual carrying an allele with normal function (*<italic>1</italic>) and another with reduced function (*<italic>2</italic> or *<italic>3</italic>) configures a genotype or diplotype (<italic>CYP2C9*1/*2</italic> or <italic>CYP2C9*1/*3</italic>) predictor intermediate metabolism (<abbrev xlink:title="intermediate metabolism" id="ABBRID0ETLAE">IM</abbrev>) (<xref ref-type="bibr" rid="B19">Caudle et al. 2014</xref>; <xref ref-type="bibr" rid="B3">Alvarado et al. 2019</xref>); carriers of two reduced function alleles (*<italic>2</italic> or *<italic>3</italic>) configure diplotypes (<italic>CYP2C9*2/*2</italic>, <italic>CYP2C9*2/*3</italic> or <italic>CYP2C9*3/*3</italic>) predictors of poor metabolism (<abbrev xlink:title="poor metabolism" id="ABBRID0EJMAE">PM</abbrev>) (<xref ref-type="bibr" rid="B45">Hirota et al. 2013</xref>; <xref ref-type="bibr" rid="B19">Caudle et al. 2014</xref>).</p>
        <p>The <italic>CYP2C9</italic> enzyme (member of the mixed-function oxidase system, cytochrome P450: EC 1.14.13.48) is a 490-amino acid protein (<xref ref-type="bibr" rid="B70">Pinto and Dolan 2011</xref>; <xref ref-type="bibr" rid="B45">Hirota et al. 2013</xref>); represents 18% of the CYP proteins in liver microsomes (<xref ref-type="bibr" rid="B70">Pinto and Dolan 2011</xref>), and metabolizes approximately 15% of drugs, including antiepileptics, anticoagulants, antihypertensives, nonsteroidal anti-inflammatory drugs (<xref ref-type="bibr" rid="B67">Mukai et al. 2017</xref>), and sulfonylureas (glibenclamide) (<xref ref-type="bibr" rid="B6">Alvarado et al. 2021c</xref>). The frequencies of <italic>CYP2C9*2</italic> and <italic>CYP2C9*3</italic> alleles differ between ethnic groups and depend on the geographic location of a given population, being higher in Caucasians than in Africans and Asians (<xref ref-type="bibr" rid="B19">Caudle et al. 2014</xref>; <xref ref-type="bibr" rid="B20">Céspedes-Garro et al. 2015</xref>); <italic>CYP2C9*3</italic> is present in Caucasians with allele frequencies of 4% to 10% (<xref ref-type="bibr" rid="B64">Mittal et al. 2015</xref>), 4% in Asians and Indians (<xref ref-type="bibr" rid="B42">Henderson et al. 2019</xref>). Regarding genotypes, <italic>CYP2C9*1/*2</italic>, <italic>CYP2C9*1/*3</italic>, and <italic>CYP2C9*2/*2</italic> have been described in Caucasians (<xref ref-type="bibr" rid="B33">Fricke-Galindo et al. 2018</xref>); <italic>CYP2C9*3/*3</italic> in Indian (<xref ref-type="bibr" rid="B45">Hirota et al. 2013</xref>; <xref ref-type="bibr" rid="B75">Seven et al. 2014</xref>); <italic>CYP2C9*1/*3</italic> and <italic>CYP2C19*1/*3</italic> in Japanese (<xref ref-type="bibr" rid="B64">Mittal et al. 2015</xref>); <italic>CYP2C9*6/*6</italic> and <italic>CYP2C19*1/*1</italic> in African American populations (<xref ref-type="bibr" rid="B33">Fricke-Galindo et al. 2018</xref>).</p>
      </sec>
      <sec sec-type="﻿CYP2C19 gene" id="SECID0EHPAE">
        <title>﻿<italic>CYP2C19</italic> gene</title>
        <p>The <italic>CYP2C19</italic> gene is located at locus 10q24.1 of chromosome 10 (long arm of chromosome 10 in region 24) where the coding sequence is 1473 bp, consists of 9 exons and 8 introns, encodes a protein of 490 residues of amino acids; presents more than 35 allelic variants and subvariants (<xref ref-type="bibr" rid="B79">Sim et al. 2006</xref>; <xref ref-type="bibr" rid="B99">Yin and Miyata 2011</xref>; <xref ref-type="bibr" rid="B61">Maruf et al. 2019</xref>); most individuals have <italic>CYP2C19*1</italic>, *<italic>2</italic>, *<italic>3</italic>, and *<italic>17</italic> (<xref ref-type="bibr" rid="B30">Dehbozorgi et al. 2018</xref>). The wild type <italic>CYP2C19*1</italic> allele encodes the protein with 100% function; <italic>CYP2C19*2</italic> GA (rs4244285, 681G&gt;A) is the most common allele that is produced by a transition from guanine (G) to adenine (A) at position 681 (c.681G&gt;A) of exon 5, creating a site of aberrant splicing that alters the reading frame of the mRNA beginning at amino acid 215 and produces a 20 amino acid premature stop codon and non-functional protein is expressed (<xref ref-type="bibr" rid="B79">Sim et al. 2006</xref>; <xref ref-type="bibr" rid="B53">Lee 2013</xref>; <xref ref-type="bibr" rid="B30">Dehbozorgi et al. 2018</xref>; <xref ref-type="bibr" rid="B61">Maruf et al. 2019</xref>). The most important is <italic>CYP2C19*3</italic> (rs4986893, 683G&gt;A) which has a point mutation (683G&gt;A) in exon 4 resulting in a premature stop codon and therefore a non-functional protein (<xref ref-type="bibr" rid="B41">Hamdy et al. 2002</xref>; <xref ref-type="bibr" rid="B71">Saeed and Mayet 2013</xref>; <xref ref-type="bibr" rid="B30">Dehbozorgi et al. 2018</xref>; <xref ref-type="bibr" rid="B15">Bousman et al. 2019</xref>). <italic>CYP2C19*17</italic> (rs12248560, g. -806C&gt;T) is a single nucleotide polymorphism of the 5’ promoter region (g. -806C&gt;T) that results in the change of Cys806Thr and the binding of region-specific nuclear proteins flanking 5’; this union increases the transcription of genes that encode proteins of greater metabolic function (<xref ref-type="bibr" rid="B79">Sim et al. 2006</xref>; <xref ref-type="bibr" rid="B53">Lee 2013</xref>; <xref ref-type="bibr" rid="B30">Dehbozorgi et al. 2018</xref>; <xref ref-type="bibr" rid="B81">Skadrić and Stojković 2020</xref>). <italic>CYP2C19*4</italic> (A&gt;G in the start codon), <italic>CYP2C19*5</italic> (1297C&gt;T) in the heme-binding region leading to an Arg433Trp substitution, <italic>CYP2C19*6</italic> (395G&gt;A) in exon 3 generating Arg132Gln substitution, <italic>CYP2C19*7</italic> (T&gt;A) at the 5’ donor splice site of intron 5, <italic>CYP2C19*8</italic> (358T&gt;C) in exon 3 generating Trp120Arg substitution, <italic>CYP2C19*16</italic> (1324C&gt;T) in exon 9 located near the heme binding region resulting in an Arg442Cys substitution (<xref ref-type="bibr" rid="B53">Lee 2013</xref>).</p>
        <p>This gene encodes the CYP2C19 protein that metabolizes valproic acid, carbamazepine, and phenytoin; antidepressants (citalopram, escitalopram, sertraline, amitriptyline, clomipramine, doxepin, imipramine, and trimipramine), anticoagulants (clopidogrel), nonsteroidal anti-inflammatory drugs (<abbrev xlink:title="nonsteroidal anti-inflammatory drugs" id="ABBRID0EUSAE">NSAIDs</abbrev>), antihypertensives (propranolol), diazepam, proton pump inhibitors (<abbrev xlink:title="proton pump inhibitors" id="ABBRID0EYSAE">PPIs</abbrev>), and others (<xref ref-type="bibr" rid="B15">Bousman et al. 2019</xref>; <xref ref-type="bibr" rid="B81">Skadrić and Stojković 2020</xref>). Regarding the metabolic phenotype, it is indicated that an individual who carries two alleles of normal function (*<italic>1</italic>) inherited from mother and mother configures a genotype or diplotype (<italic>CYP2C19*1/*1</italic>) predictive of normal metabolism (<abbrev xlink:title="normal metabolizers" id="ABBRID0EITAE">NM</abbrev>) (<xref ref-type="bibr" rid="B73">Scott et al. 2013</xref>); carriers of the <italic>CYP2C19*2</italic> and <italic>CYP2C19*3</italic> alleles form diplotypes that are predictors of poor metabolizers (<abbrev xlink:title="poor metabolizer" id="ABBRID0EUTAE">PM</abbrev>) (<xref ref-type="bibr" rid="B96">Wang et al. 2011</xref>), and the most frequent in Asians (<xref ref-type="bibr" rid="B41">Hamdy et al. 2002</xref>); and <italic>CYP2C19*17</italic> carriers configure predictive diplotypes of ultra-extensive metabolizers (<abbrev xlink:title="ultra-extensive metabolizers" id="ABBRID0ECUAE">URMs</abbrev>) (<xref ref-type="bibr" rid="B23">Chaudhry et al. 2008</xref>; <xref ref-type="bibr" rid="B37">Gawrońska-Szklarz et al. 2012</xref>).</p>
        <p>The frequency of metabolizers, poor metabolizers (<abbrev xlink:title="poor metabolizer" id="ABBRID0EQUAE">PM</abbrev>) for <italic>CYP2C19</italic> has been reported in Caucasian European populations to be 2–5% (<xref ref-type="bibr" rid="B56">Lim et al. 2014</xref>; <xref ref-type="bibr" rid="B11">Alvarado et al. 2023</xref>), 2–7% in black Africans (<xref ref-type="bibr" rid="B74">Scott et al. 2011</xref>), in Asians 15 -23% (<xref ref-type="bibr" rid="B74">Scott et al. 2011</xref>; <xref ref-type="bibr" rid="B56">Lim et al. 2014</xref>), specifically 15–17% Chinese, 18–23% Japanese, and 12–16% Korean; this suggests that the <abbrev xlink:title="poor metabolizer" id="ABBRID0EKVAE">PM</abbrev> phenotype is an autosomal recessive trait that is inherited (<xref ref-type="bibr" rid="B88">Tabari et al. 2013</xref>). <italic>CYP2C19*2</italic> represents 93% in Europeans and 75% in East or East Asians (China, South Korea, and Japan) (<xref ref-type="bibr" rid="B88">Tabari et al. 2013</xref>; <xref ref-type="bibr" rid="B63">Mirzaev et al. 2017</xref>), and in Hispanics it is 12.6% (<xref ref-type="bibr" rid="B63">Mirzaev et al. 2017</xref>); <italic>CYP2C19*3</italic> represents 25% in Asians, being specific to these populations, which is why they are rare in other populations (<xref ref-type="bibr" rid="B26">Chen et al. 2009</xref>; <xref ref-type="bibr" rid="B88">Tabari et al. 2013</xref>). The frequency of <italic>CYP2C19*17</italic> in Europeans is 18–28%, Africans 17–18%, and 0.3–4% in Asians (<xref ref-type="bibr" rid="B37">Gawrońska-Szklarz et al. 2012</xref>; Saeed et al. 2013). Table <xref ref-type="table" rid="T2">2</xref> summarizes the polymorphisms of the <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genes that are most relevant in the metabolism of antiepileptic drugs. Updated <italic>CYP2C9*2/*2</italic> diplotype (AS = 1) now predicts <abbrev xlink:title="intermediate metabolism" id="ABBRID0E1WAE">IM</abbrev> phenotype (originally predicted <abbrev xlink:title="poor metabolizer" id="ABBRID0E5WAE">PM</abbrev>), this change is based on data from multiple substrates (celecoxib, flurbiprofen, phenytoin and warfarin) showing an effect similar to <italic>CYP2C9*1/*3</italic> diplotype (AS = 1) and <italic>CYP2C9*2/*2</italic> in metabolic ratio and dose (warfarin). In addition, <italic>CYP2C9*3</italic> is classified as “no function” alleles with a value of 0 for the AS calculation, this is based on the <italic>CYP2C9*3/*3</italic> diplotype with lowest metabolic activity and slowest pharmacokinetic clearance (<xref ref-type="bibr" rid="B51">Karnes et al. 2021</xref>).</p>
        <table-wrap id="T1" position="float" orientation="portrait">
          <label>Table 1.</label>
          <caption>
            <p>Pharmacokinetic parameters of valproic acid, carbamazepine, and phenytoin.</p>
          </caption>
          <table id="TID0ENVDI" rules="all">
            <tbody>
              <tr>
                <th rowspan="1" colspan="1">Drug</th>
                <th rowspan="1" colspan="1">F (%)</th>
                <th rowspan="1" colspan="1">t<sub>max</sub> (h)</th>
                <th rowspan="1" colspan="1">C<sub>mE</sub> (mg/L)</th>
                <th rowspan="1" colspan="1">UP (%)</th>
                <th rowspan="1" colspan="1">Vd (L/kg)</th>
                <th rowspan="1" colspan="1">t<sub>1/2</sub> (h)</th>
                <th rowspan="1" colspan="1">Enzyme</th>
                <th rowspan="1" colspan="1">Reference</th>
              </tr>
              <tr>
                <td rowspan="4" colspan="1">Valproic acid</td>
                <td rowspan="4" colspan="1">95</td>
                <td rowspan="4" colspan="1">1.5</td>
                <td rowspan="4" colspan="1">50</td>
                <td rowspan="4" colspan="1">90</td>
                <td rowspan="4" colspan="1">0.1–0.4</td>
                <td rowspan="4" colspan="1">4–20</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9</italic>
                </td>
                <td rowspan="4" colspan="1">(<xref ref-type="bibr" rid="B31">Doré et al. 2017</xref>; <xref ref-type="bibr" rid="B9">Alvarado et al. 2022c</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2A6</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2B6</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="5" colspan="1">Carbamazepine</td>
                <td rowspan="5" colspan="1">70–85</td>
                <td rowspan="5" colspan="1">4–8</td>
                <td rowspan="5" colspan="1">4</td>
                <td rowspan="5" colspan="1">75–85</td>
                <td rowspan="5" colspan="1">1.4</td>
                <td rowspan="5" colspan="1">8–20</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9</italic>
                </td>
                <td rowspan="5" colspan="1">(<xref ref-type="bibr" rid="B2">Aldaz et al. 2011</xref>; <xref ref-type="bibr" rid="B39">Gierbolini et al. 2016</xref>; <xref ref-type="bibr" rid="B8">Alvarado et al. 2022b</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP3A4</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2B6</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP3A7</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">Phenytoin</td>
                <td rowspan="2" colspan="1">80</td>
                <td rowspan="2" colspan="1">3–12</td>
                <td rowspan="2" colspan="1">10</td>
                <td rowspan="2" colspan="1">90</td>
                <td rowspan="2" colspan="1">0.6–0.7</td>
                <td rowspan="2" colspan="1">8–60</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9</italic>
                </td>
                <td rowspan="2" colspan="1">(Lopez-Garcia et al. 2014; <xref ref-type="bibr" rid="B12">Balestrini and Sisodiya 2018</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19</italic>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="T2" position="float" orientation="portrait">
          <label>Table 2.</label>
          <caption>
            <p>Characteristics of the <italic>CYP2C9</italic> and <italic>CYPC19</italic> genes and their phenotypes.</p>
          </caption>
          <table id="TID0EP5DI" rules="all">
            <tbody>
              <tr>
                <th rowspan="1" colspan="1">Allele</th>
                <th rowspan="1" colspan="1">Nucleotide change (cDNA)</th>
                <th rowspan="1" colspan="1">Diplotype</th>
                <th rowspan="1" colspan="1">Phenotype</th>
                <th rowspan="1" colspan="1">Activity score</th>
                <th rowspan="1" colspan="1">Reference</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="6">
                  <bold>Gene/chromosome: <italic>CYP2C9</italic>/10q24</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*1</italic>
                </td>
                <td rowspan="1" colspan="1">None</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*1/*1</italic>
                </td>
                <td rowspan="1" colspan="1">
                  <abbrev xlink:title="normal metabolizers" id="ABBRID0ESAAG">NM</abbrev>
                </td>
                <td rowspan="1" colspan="1">2</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B51">Karnes et al. 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C9*2</italic>
                </td>
                <td rowspan="1" colspan="1">430C&gt;T</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*1/*2</italic>
                </td>
                <td rowspan="2" colspan="1">
                  <abbrev xlink:title="intermediate metabolism" id="ABBRID0EVBAG">IM</abbrev>
                </td>
                <td rowspan="1" colspan="1">1.5</td>
                <td rowspan="2" colspan="1">(<xref ref-type="bibr" rid="B51">Karnes et al. 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">(rs1799853)</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2/*2</italic>
                </td>
                <td rowspan="1" colspan="1">1</td>
              </tr>
              <tr>
                <td rowspan="3" colspan="1">
                  <italic>CYP2C9*3</italic>
                </td>
                <td rowspan="2" colspan="1">1075A&gt;C</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*1/*3</italic>
                </td>
                <td rowspan="1" colspan="1">
                  <abbrev xlink:title="intermediate metabolism" id="ABBRID0EFDAG">IM</abbrev>
                </td>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="3" colspan="1">(<xref ref-type="bibr" rid="B51">Karnes et al. 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2/*3</italic>
                </td>
                <td rowspan="1" colspan="1">
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0E6DAG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">0.5</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">(rs1057910)</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3/*3</italic>
                </td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">CYP2C9*<italic>5</italic></td>
                <td rowspan="1" colspan="1">delA818</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*5/*5</italic>
                </td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B51">Karnes et al. 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="6">
                  <bold>Gene/chromosome: <italic>CYP2C19</italic>/10q24</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*1</italic>
                </td>
                <td rowspan="1" colspan="1">None</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*1/*1</italic>
                </td>
                <td rowspan="1" colspan="1">
                  <abbrev xlink:title="normal metabolizers" id="ABBRID0ERGAG">NM</abbrev>
                </td>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B20">Céspedes-Garro et al. 2015</xref>; <xref ref-type="bibr" rid="B61">Maruf et al. 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C19*2</italic>
                </td>
                <td rowspan="1" colspan="1">681G&gt;A</td>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C19*1/*2</italic>
                </td>
                <td rowspan="2" colspan="1">
                  <abbrev xlink:title="intermediate metabolism" id="ABBRID0EYHAG">IM</abbrev>
                </td>
                <td rowspan="2" colspan="1">0.5</td>
                <td rowspan="2" colspan="1">(<xref ref-type="bibr" rid="B20">Céspedes-Garro et al. 2015</xref>; <xref ref-type="bibr" rid="B61">Maruf et al. 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">(rs4244285)</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C19*2</italic>
                </td>
                <td rowspan="1" colspan="1">681G&gt;A</td>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C19*2/*2</italic>
                </td>
                <td rowspan="9" colspan="1">
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EDJAG">PM</abbrev>
                </td>
                <td rowspan="9" colspan="1">0</td>
                <td rowspan="9" colspan="1">(<xref ref-type="bibr" rid="B20">Céspedes-Garro et al. 2015</xref>; <xref ref-type="bibr" rid="B61">Maruf et al. 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">(rs4244285)</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C19*3</italic>
                </td>
                <td rowspan="1" colspan="1">636G&gt;A</td>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C19*3/*3</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">(rs4986893)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*4</italic>
                </td>
                <td rowspan="1" colspan="1">A&gt;G</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*4/*4</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*5</italic>
                </td>
                <td rowspan="1" colspan="1">1297C&gt;T</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*5/*5</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*6</italic>
                </td>
                <td rowspan="1" colspan="1">395G&gt;A</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*6/*6</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*7</italic>
                </td>
                <td rowspan="1" colspan="1">T&gt;A</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*7/*7</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*8</italic>
                </td>
                <td rowspan="1" colspan="1">358T&gt;C</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*8/*8</italic>
                </td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">
                  <italic>CYP2C19*17</italic>
                </td>
                <td rowspan="1" colspan="1">-806C&gt;T</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*1/*17</italic>
                </td>
                <td rowspan="2" colspan="1">UM</td>
                <td rowspan="2" colspan="1">2</td>
                <td rowspan="2" colspan="1">(<xref ref-type="bibr" rid="B20">Céspedes-Garro et al. 2015</xref>; <xref ref-type="bibr" rid="B61">Maruf et al. 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">(rs12248560)</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*17/*17</italic>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Activity score and genotype: 2 an individual carrying two normal function alleles; 1.5 an individual carrying one allele of normal function plus one allele of decreased function; 1 one allele of normal function plus one allele without function or two alleles of decreased function; 0.5 an individual carrying a non-function allele plus a decreased-function allele; 0 two alleles without function.</p>
      </sec>
      <sec sec-type="﻿CYP2C9 and CYP2C19 associated with adverse reactions" id="SECID0ELOAG">
        <title>﻿<italic>CYP2C9</italic> and <italic>CYP2C19</italic> associated with adverse reactions</title>
        <p>Therapeutic drug monitoring is often used to adjust the dose to maintain serum concentrations within the therapeutic range, that is, the drug must exceed the minimum effective concentration (C<sub>mE</sub>) to avoid therapeutic failure or resistance to treatment; but it must not exceed the minimum toxic concentration (C<sub>MT</sub>), to avoid adverse reactions and toxicity of antiepileptic drugs; Therefore, therapeutic ranges of 10–20 mg/L phenytoin (<abbrev xlink:title="phenytoin" id="ABBRID0E1OAG">PHT</abbrev>) have been proposed (<xref ref-type="bibr" rid="B7">Alvarado et al. 2022a</xref>), 4–12 mg/L carbamazepine (<abbrev xlink:title="carbamazepine" id="ABBRID0ECPAG">CBZ</abbrev>) (<xref ref-type="bibr" rid="B8">Alvarado et al. 2022b</xref>), 50–100 mg/L for valproic acid (<abbrev xlink:title="valproic acid" id="ABBRID0EKPAG">VPA</abbrev>) (<xref ref-type="bibr" rid="B9">Alvarado et al. 2022c</xref>); the <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genes are implicated in said serum levels of antiepileptic drugs. Five observational studies were evaluated, 2 case-control, 1 cohort, 8 review, and 4 systematic review and meta-analysis for the association between <italic>CYP2C9/CYP2C19</italic> single nucleotide polymorphisms (<abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EYPAG">SNPs</abbrev>) and their association on plasma level and reactions adverse. In the study by Song et al. included 83 patients with epilepsy who were treated as sustained-release <abbrev xlink:title="valproic acid" id="ABBRID0E3PAG">VPA</abbrev> monotherapy. The <abbrev xlink:title="valproic acid" id="ABBRID0EAQAG">VPA</abbrev> concentration-dose relationship was significantly lower in <italic>CYP2C19*1/*1</italic><abbrev xlink:title="normal metabolizers" id="ABBRID0EGQAG">NM</abbrev> (3.33±1.78) compared to <italic>CYP2C19*1/*2</italic><abbrev xlink:title="intermediate metabolism" id="ABBRID0EMQAG">IM</abbrev> (4.45±1.42) and <italic>CYP2C19*3/*3</italic><abbrev xlink:title="poor metabolizer" id="ABBRID0ESQAG">PM</abbrev> (6.64±1.06). An association was found between the <italic>CYP2C19*2</italic> and <italic>CYP2C19*3</italic> alleles with serum <abbrev xlink:title="valproic acid" id="ABBRID0E1QAG">VPA</abbrev> concentration, whereas the <italic>CYP2C9*13</italic> allele had no effect on plasma <abbrev xlink:title="valproic acid" id="ABBRID0EARAG">VPA</abbrev> concentration (p = 0.809) (<xref ref-type="bibr" rid="B83">Song et al. 2022</xref>). In patients carrying <italic>CYP2C9*1/*3</italic> alleles, <xref ref-type="bibr" rid="B89">Tan et al. (2010)</xref> have observed in patients with Han-Chinese epilepsy an increase in the serum level of <abbrev xlink:title="valproic acid" id="ABBRID0EORAG">VPA</abbrev> compared to the wild type (3.9±0.4 µg/ml/mg dose/kg bw vs 3.4±0.4 µg/ml/ mg dose/kg bw, p = 0.0001) (<xref ref-type="bibr" rid="B89">Tan et al. 2010</xref>). In another study, Suvichapanich et al. analyzed the association between the <italic>CYP2C9*3</italic> allelic variant and <abbrev xlink:title="phenytoin" id="ABBRID0EYRAG">PHT</abbrev>-induced severe skin adverse reactions (<abbrev xlink:title="severe cutaneous adverse reactions" id="ABBRID0E3RAG">SCARs</abbrev>) in Thai children with epilepsy. Thirty-seven patients with antiepileptic drug-induced SCAR (n = 20 phenobarbital and n = 17 phenytoin) and 35 patients with tolerance (n = 19 phenobarbital and n = 16 phenytoin) were included. A significant association was found between <italic>CYP2C9*3</italic> and <abbrev xlink:title="phenytoin" id="ABBRID0ECSAG">PHT</abbrev>-induced SCAR (Odds ratio, OR = 14.52; 95% confidence interval (CI) 1.18; p value = 0.044). No association was found between CYP2C9*<italic>3</italic> and phenobarbital-induced <abbrev xlink:title="severe cutaneous adverse reactions" id="ABBRID0EISAG">SCARs</abbrev> (<xref ref-type="bibr" rid="B87">Suvichapanich et al. 2015</xref>). Ortega-Vazquez et al. conducted a study in 64 mestizo mexican patients with epilepsy treated with <abbrev xlink:title="phenytoin" id="ABBRID0EQSAG">PHT</abbrev> monotherapy (n = 25) and combination therapy (phenytoin, carbamazepine, valproate, phenobarbital, and others; n = 39), and in 300 healthy volunteers. In multivariate models, the intronic variant IVS8-109T CYP2C9 was significantly associated with higher plasma <abbrev xlink:title="phenytoin" id="ABBRID0EUSAG">PHT</abbrev> concentrations (p = 0.03); this allele was more frequent in the group with supratherapeutic serum levels compared to the subtherapeutic group (0.13 vs. 0.03, respectively; p = 0.05, Fisher’s exact test). The <italic>CYP2C19*3</italic> allele was not identified in patients or volunteers. The results suggest that <italic>CYP2C9</italic> IVS8-109T may decrease the enzymatic activity of CYP2C9 in <abbrev xlink:title="phenytoin" id="ABBRID0E3SAG">PHT</abbrev>. More research is needed to confirm the findings (Ortega-Vazquez et al. 2016).</p>
        <p>Meanwhile, Yampayon et al. investigated the association of the <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genes with SCAR induced by <abbrev xlink:title="phenytoin" id="ABBRID0EGTAG">PHT</abbrev>. The study included 36 Thai patients (15 with Stevens-Johnson syndrome (<abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EKTAG">SJS</abbrev>) and 21 with drug rash with eosinophilia and systemic symptoms (DRESS)/drug hypersensitivity syndrome (DHS)) and 100 <abbrev xlink:title="phenytoin" id="ABBRID0EOTAG">PHT</abbrev>-tolerant controls were studied. A <italic>CYP2C9*3</italic> association of significant risk of <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EUTAG">SJS</abbrev> was found (adjusted OR 5.40, p = 0.0097) (<xref ref-type="bibr" rid="B98">Yampayon et al. 2017</xref>). Hikino et al. conducted a case-control study with a total of 747 Japanese patients (24 cases and 723 tolerant controls). <italic>CYP2C9*3</italic> carriers were found to be significantly associated with <abbrev xlink:title="phenytoin" id="ABBRID0E5TAG">PHT</abbrev>-induced rashes (OD 7.05, 95% CI 2.44–20.4, p = 0.0022) (<xref ref-type="bibr" rid="B44">Hikino et al. 2020</xref>). Sukasem et al. conducted a retrospective study of cases (88 <abbrev xlink:title="phenytoin" id="ABBRID0EGUAG">PHT</abbrev>-treated patients) and controls (70 <abbrev xlink:title="phenytoin" id="ABBRID0EKUAG">PHT</abbrev>-tolerant patients) during 2008–2017. <italic>CYP2C9*3</italic> was found to contribute to an increased risk of <abbrev xlink:title="phenytoin" id="ABBRID0EQUAG">PHT</abbrev>-induced <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EUUAG">SJS</abbrev>/toxic epidermal necrolysis (<abbrev xlink:title="epidermal necrolysis" id="ABBRID0EYUAG">TEN</abbrev>), with the statistical association being weak (OR 4.800; 95% CI 0.960–23.990; p = 0.056) (<xref ref-type="bibr" rid="B86">Sukasem et al. 2020</xref>). Fohner et al. in a cohort study of multi-ethnic resources for genetic epidemiology research on adult health and aging, included 382 participants who received a prescription for <abbrev xlink:title="phenytoin" id="ABBRID0EAVAG">PHT</abbrev> (at a dose of 300 mg/ day) between 2005 and 2017. Included participants self-identified as Asian (n = 21), Black (n = 18), White Hispanic (n = 29), and 308 as non-Hispanic White. The frequencies of the <italic>CYP2C9*2</italic> and <italic>CYP2C9*3</italic> alleles were 12.0% and 4.7%, respectively; 20% <italic>CYP2C19*17</italic>, 17% <italic>CYP2C19*2</italic> and 1% <italic>CYP2C19*3</italic>. Intermediate metabolizers carrying <italic>CYP2C9*1/*3</italic> or <italic>CYP2C9*2/*2</italic> genotypes were found to be more likely to develop cutaneous adverse reactions compared with <italic>CYP2C9*1/*1</italic> participant (OD 4.47; 95% CI 1.64–11.69, p &lt; 0.01). Asian participants were 3.70 times more likely to experience a skin adverse reaction compared with non-Hispanic white participants (95% CI 0.95–12.13; p = 0.04). The association of <italic>CYP2C19</italic> with adverse reactions could not be demonstrated (<xref ref-type="bibr" rid="B34">Fohner et al. 2020</xref>). Orsini et al. found that the <italic>CYP2C9*2</italic> and <italic>CYP2C9*3</italic> single nucleotide polymorphisms (<abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0E5VAG">SNPs</abbrev>) are involved in the expression of CYP2C9 enzymes that metabolize <abbrev xlink:title="valproic acid" id="ABBRID0ECWAG">VPA</abbrev>, and whose metabolite 4-ene-<abbrev xlink:title="valproic acid" id="ABBRID0EGWAG">VPA</abbrev> is associated with severe hyperammonemia and nonalcoholic fatty liver disease. Also, decreasing the dose of <abbrev xlink:title="valproic acid" id="ABBRID0EKWAG">VPA</abbrev> in patients with CYP2C9 carriers has been shown to improve hyperammonemia (<xref ref-type="bibr" rid="B68">Orsini et al. 2018</xref>). Monostory et al. observed that the allelic variants <italic>CYP2C9*2</italic> or <italic>CYP2C9*3</italic> show a significant reduction in <abbrev xlink:title="valproic acid" id="ABBRID0EWWAG">VPA</abbrev> metabolism in children, which increases serum levels of the drug and induces adverse reactions, compared to the wild-type <italic>CYP2C9*1/*1</italic> genotype (<xref ref-type="bibr" rid="B65">Monostory et al. 2019</xref>). Iannaccone et al. found that the <italic>CYP2C19*2</italic> and <italic>CYP2C19*3</italic><abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EEXAG">SNPs</abbrev> have been associated with <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EIXAG">SJS</abbrev>/<abbrev xlink:title="epidermal necrolysis" id="ABBRID0EMXAG">TEN</abbrev> after <abbrev xlink:title="carbamazepine" id="ABBRID0EQXAG">CBZ</abbrev> administration. <italic>CYP2C9*3</italic> and <italic>CYP2C9*2</italic> carriers generate heterozygous <italic>CYP2C9*2/*3</italic> diplotypes that predict poor metabolizers, and in them, serum <abbrev xlink:title="valproic acid" id="ABBRID0E1XAG">VPA</abbrev> levels are elevated compared to the wild-type <italic>CYP2C9*1</italic> allele. <italic>CYP2C19*2</italic> carriers require higher doses of <abbrev xlink:title="valproic acid" id="ABBRID0ECYAG">VPA</abbrev> to achieve steady-state serum concentrations (<xref ref-type="bibr" rid="B46">Iannaccone et al. 2021</xref>). Ahmed et al. reviewed an association study between <italic>CYP2C9*3</italic> with a 95% reduction of <abbrev xlink:title="phenytoin" id="ABBRID0EMYAG">PHT</abbrev> metabolism and the induction of SCAR. Thai patients treated with <abbrev xlink:title="carbamazepine" id="ABBRID0EQYAG">CBZ</abbrev> and <abbrev xlink:title="phenytoin" id="ABBRID0EUYAG">PHT</abbrev>, and with <italic>CYP2C19*2</italic> genotype had a higher probability of developing SCAR compared with patients with wild-type <italic>CYP2C19</italic>; although the result was not statistically significant (OR 2.5, 95% CI 0.96–67.3; p = 0.06) (<xref ref-type="bibr" rid="B1">Ahmed et al. 2021</xref>). Fowler et al. reviewed the relationship of <italic>CYP2C9</italic> and <abbrev xlink:title="phenytoin" id="ABBRID0ECZAG">PHT</abbrev> adverse reactions; it is indicated that <italic>CYP2C9</italic><abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EIZAG">SNPs</abbrev> are probably responsible for increasing the toxic arene oxide metabolites, which increase the probability of SCAR, such as <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EMZAG">SJS</abbrev> and <abbrev xlink:title="epidermal necrolysis" id="ABBRID0EQZAG">TEN</abbrev>; consider that <abbrev xlink:title="valproic acid" id="ABBRID0EUZAG">VPA</abbrev> is a CYP2C9 inhibitor, generating the same adverse reactions induced by phenytoin (<xref ref-type="bibr" rid="B35">Fowler et al. 2019</xref>). Chang et al. found that 97.7% of patients from Han-China with <italic>CYP2C9*3</italic> genotype are significantly associated with the development of <abbrev xlink:title="phenytoin" id="ABBRID0E5ZAG">PHT</abbrev>-induced maculopapular rash (OR 167; p = 0.007), with <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EC1AG">SJS</abbrev> and <abbrev xlink:title="epidermal necrolysis" id="ABBRID0EG1AG">TEN</abbrev> induced by <abbrev xlink:title="phenytoin" id="ABBRID0EK1AG">PHT</abbrev> (OR 30; 95% CI 8.4–109; p = 1.2 × 10–10); A significant association was also found between <italic>CYP2C9*3</italic> with <abbrev xlink:title="phenytoin" id="ABBRID0EQ1AG">PHT</abbrev>-induced <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EU1AG">SJS</abbrev>/<abbrev xlink:title="epidermal necrolysis" id="ABBRID0EY1AG">TEN</abbrev> in Japanese patients (OR 8.9; 95% CI 2.2–35.8; p = 0.010), and in Malaysian patients (OR 8.4; 95% CI 1.5–48.5, p = 0.045). <italic>CYP2C9*3</italic> was found to be associated with low metabolism and high serum <abbrev xlink:title="phenytoin" id="ABBRID0E51AG">PHT</abbrev> levels (17 μg/mL), compared to drug-tolerant control patients (2.5 μg/mL) (p = 0.0002). The <italic>CYP2C19*3</italic> variant is associated with adverse reactions induced by <abbrev xlink:title="phenytoin" id="ABBRID0EE2AG">PHT</abbrev> (OR 4.47; 95% CI 1.09–18.36; p = 0.048); no significant association was found between <italic>CYP2C19*2</italic> and <italic>CYP2C19*17</italic>, and <abbrev xlink:title="phenytoin" id="ABBRID0EM2AG">PHT</abbrev>-induced adverse reactions (<xref ref-type="bibr" rid="B24">Chang et al. 2020</xref>). Silvado et al. showed that the maintenance dose of <abbrev xlink:title="phenytoin" id="ABBRID0EU2AG">PHT</abbrev> (5–10 mg/kg/day) should be reduced by 25% in <abbrev xlink:title="intermediate metabolism" id="ABBRID0EY2AG">IM</abbrev> patients (<italic>CYP2C9*1/*2</italic> or *<italic>1/*3</italic> diplotypes) and 50% in <abbrev xlink:title="poor metabolizer" id="ABBRID0EA3AG">PM</abbrev> (<italic>CYP2C9*2/*3</italic> or *<italic>3/*3</italic>) to reduce the risk of <abbrev xlink:title="phenytoin" id="ABBRID0EI3AG">PHT</abbrev>-induced adverse reactions (<xref ref-type="bibr" rid="B77">Silvado et al. 2018</xref>). Shnayder et al. mentions that the <italic>CYP2C9*2</italic> and <italic>CYP2C9*3</italic><abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EU3AG">SNPs</abbrev> are associated with decreased <abbrev xlink:title="valproic acid" id="ABBRID0EY3AG">VPA</abbrev> metabolism, so patients who are homozygous for <italic>CYP2C9*2</italic> or <italic>CYP2C9*3</italic> or who are heterozygous (<italic>CYP2C9*2/*3</italic>) have a <abbrev xlink:title="poor metabolizer" id="ABBRID0EC4AG">PM</abbrev> phenotype and show decreased p-oxidation of <abbrev xlink:title="valproic acid" id="ABBRID0EG4AG">VPA</abbrev> in liver microsomes. <italic>CYP2C9*2/*3</italic> catalyzed the formation of the toxic metabolites 4-ene-<abbrev xlink:title="valproic acid" id="ABBRID0EM4AG">VPA</abbrev>, 4-OH-<abbrev xlink:title="valproic acid" id="ABBRID0EQ4AG">VPA</abbrev>, and 5-OH-<abbrev xlink:title="valproic acid" id="ABBRID0EU4AG">VPA</abbrev> (<xref ref-type="bibr" rid="B76">Shnayder et al. 2023</xref>). While Yoon et al. found in six studies with 807 patients a significant association between CYP2C9*<italic>3</italic> with the plasmatic concentration of <abbrev xlink:title="valproic acid" id="ABBRID0E54AG">VPA</abbrev>; said concentration was 0.70 μg/mL higher per mg/kg compared to non-carriers of the <italic>CYP2C9*3</italic> genotype (95% CI 0.25–1.15; p = 0.002) (<xref ref-type="bibr" rid="B100">Yoon et al. 2020</xref>). Wu et al. conducted a systematic review study and meta-analysis of the association of <italic>CYP2C9*3</italic> with <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EK5AG">SJS</abbrev> and <abbrev xlink:title="epidermal necrolysis" id="ABBRID0EO5AG">TEN</abbrev><abbrev xlink:title="phenytoin" id="ABBRID0ES5AG">PHT</abbrev>-induced. Four studies with 117 <abbrev xlink:title="phenytoin" id="ABBRID0EW5AG">PHT</abbrev>-induced <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0E15AG">SJS</abbrev>/<abbrev xlink:title="epidermal necrolysis" id="ABBRID0E55AG">TEN</abbrev> cases and 338 matched controls (<abbrev xlink:title="phenytoin" id="ABBRID0EC6AG">PHT</abbrev>-tolerant patients) or 4231 general population controls were included. A significant association was found between <italic>CYP2C9*3</italic> and <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EI6AG">SJS</abbrev>/<abbrev xlink:title="epidermal necrolysis" id="ABBRID0EM6AG">TEN</abbrev> compared with matched controls (OR 8.93; 95% CI 2.63–30.36; p = 0.0005; substantial heterogeneity I<sup>2</sup> 46%) and control population (OR 8.88, 95% CI 5.01–15.74, p &lt; 0.00001) (<xref ref-type="bibr" rid="B97">Wu et al. 2018</xref>). Su et al. performed a meta-analysis of studies that associated <abbrev xlink:title="phenytoin" id="ABBRID0EW6AG">PHT</abbrev>-induced <abbrev xlink:title="severe cutaneous adverse reactions" id="ABBRID0E16AG">SCARs</abbrev> in three groups of patients from Taiwan, Thailand, and Japan. Meta-analysis of the <italic>CYP2C9*3</italic> allele and other genes are significantly associated with <abbrev xlink:title="phenytoin" id="ABBRID0EAABG">PHT</abbrev>-induced SCAR in three Asian populations: <italic>CYP2C9*3</italic> (p = 4.66 × 10<sup>-14</sup>, OR 10.74 for Taiwan; p = 0.04, OR 3.14 for Thailand; and p = 0.04, OR = 6.21 for Japan) (<xref ref-type="bibr" rid="B85">Su et al. 2019</xref>). Kanjanasilp et al. evaluated the effects of <italic>CYP2C9</italic> and <italic>CYP2C19</italic> polymorphism on <abbrev xlink:title="phenytoin" id="ABBRID0EQABG">PHT</abbrev> pharmacokinetic parameters. Eight observational studies were included, with a total of 633 Thai patients. The Michaelis-Menten constant was significantly higher in <italic>CYP2C9</italic><abbrev xlink:title="intermediate metabolism" id="ABBRID0EWABG">IM</abbrev>/<italic>CYP2C19</italic><abbrev xlink:title="normal metabolizers" id="ABBRID0E2ABG">NM</abbrev> and <italic>CYP2C9</italic><abbrev xlink:title="intermediate metabolism" id="ABBRID0EABBG">IM</abbrev>/<italic>CYP2C19</italic><abbrev xlink:title="intermediate metabolism" id="ABBRID0EFBBG">IM</abbrev> carriers compared to control (<italic>CYP2C9</italic><abbrev xlink:title="normal metabolizers" id="ABBRID0EKBBG">NM</abbrev>/<italic>CYP2C19</italic><abbrev xlink:title="normal metabolizers" id="ABBRID0EPBBG">NM</abbrev>) groups at 2.16 and 1.55 mg/L (p &lt; 0.00001, p &lt; 0.0001). The maximum rate of action was significantly lower in control groups compared to <italic>CYP2C9</italic><abbrev xlink:title="intermediate metabolism" id="ABBRID0EUBBG">IM</abbrev>/<italic>CYP2C19</italic><abbrev xlink:title="normal metabolizers" id="ABBRID0EZBBG">NM</abbrev> and <italic>CYP2C9</italic><abbrev xlink:title="intermediate metabolism" id="ABBRID0E5BBG">IM</abbrev>/<italic>CYP2C19</italic><abbrev xlink:title="intermediate metabolism" id="ABBRID0EDCBG">IM</abbrev> carriers at 3.10 and 3.53 mg/kg/day (p = 0.00001, &lt;0.0001) (<xref ref-type="bibr" rid="B50">Kanjanasilp et al. 2021</xref>). Table <xref ref-type="table" rid="T3">3</xref> summarizes the type of study and the clinical importance of the genotypes involved in the adverse reactions of <abbrev xlink:title="antiepileptic drugs" id="ABBRID0EPCBG">AEDs</abbrev>.</p>
        <table-wrap id="T3" position="float" orientation="portrait">
          <label>Table 3.</label>
          <caption>
            <p>Type of study associated with adverse reactions and clinical implications.</p>
          </caption>
          <table id="TID0ELPAK" rules="all">
            <tbody>
              <tr>
                <th rowspan="1" colspan="1">Type of study</th>
                <th rowspan="1" colspan="1">Genotype and phenotype</th>
                <th rowspan="1" colspan="1">Clinical implication</th>
                <th rowspan="1" colspan="1">Reference</th>
              </tr>
              <tr>
                <td rowspan="5" colspan="1">Observational study</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C19*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EWDBG">IM</abbrev>
                  <italic>CYP2C19*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0E3DBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">The <italic>CYP2C19*2</italic> and *<italic>3</italic><abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EHEBG">SNPs</abbrev> are significantly associated with serum <abbrev xlink:title="valproic acid" id="ABBRID0ELEBG">VPA</abbrev> levels, and the drug dose for <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EPEBG">IM</abbrev> and <abbrev xlink:title="poor metabolizer" id="ABBRID0ETEBG">PM</abbrev> could be lower than for <abbrev xlink:title="normal metabolizer" id="ABBRID0EXEBG">NM</abbrev>.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B83">Song et al. 2022</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EKFBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1"><italic>CYP2C9</italic> variants may explain some of the substantial variability in <abbrev xlink:title="valproic acid" id="ABBRID0ETFBG">VPA</abbrev> pharmacokinetics between different subjects</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B89">Tan et al. 2010</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EGGBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1"><italic>CYP2C9*3</italic> is a predictive genetic marker to anticipate and decrease serious adverse skin reactions (<abbrev xlink:title="severe cutaneous adverse reactions" id="ABBRID0EPGBG">SCARs</abbrev>) induced by <abbrev xlink:title="phenytoin" id="ABBRID0ETGBG">PHT</abbrev>.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B87">Suvichapanich et al. 2015</xref>).</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"><italic>CYP2C9</italic> IVS8-109T</td>
                <td rowspan="1" colspan="1">Patients carrying <italic>CYP2C9</italic> IVS8-109 T showed significantly supratherapeutic serum <abbrev xlink:title="phenytoin" id="ABBRID0EMHBG">PHT</abbrev> concentrations.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B69">Ortega-Vázquez et al. 2016</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0E6HBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">Different genetic markers are associated with <abbrev xlink:title="severe cutaneous adverse reactions" id="ABBRID0EGIBG">SCARs</abbrev> induced by <abbrev xlink:title="phenytoin" id="ABBRID0EKIBG">PHT</abbrev>; It is suggested to perform genetic tests prior to treatment as predictors of SCAR induced by <abbrev xlink:title="phenytoin" id="ABBRID0EOIBG">PHT</abbrev>.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B98">Yampayon et al. 2017</xref>)</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">Cases and controls study</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EEJBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">There is a significant association of <italic>CYP2C9*3</italic> with the eruption induced by <abbrev xlink:title="phenytoin" id="ABBRID0ENJBG">PHT</abbrev>. The patient’s genotype should be verified prior to prescription to decrease the incidence of <abbrev xlink:title="phenytoin" id="ABBRID0ERJBG">PHT</abbrev>-induced rash in clinical practice.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B44">Hikino et al. 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EEKBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">Clinical and genetic factors contributed to the risk of <abbrev xlink:title="phenytoin" id="ABBRID0ELKBG">PHT</abbrev>-induced adverse reactions.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B86">Sukasem et al. 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cohort study</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EBLBG">IM</abbrev>
                </td>
                <td rowspan="1" colspan="1"><italic>CYP2C9</italic> allelic variants are associated with an increased risk of <abbrev xlink:title="phenytoin" id="ABBRID0EKLBG">PHT</abbrev>-induced cutaneous adverse reactions. It is suggested to carry out pharmacogenetic tests on patients, and based on this, prescribe the correct dose and improve the safety of the drug.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B34">Fohner et al. 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="8" colspan="1">Review study</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EAMBG">IM</abbrev>
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EGMBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">Precision medicine is the future of antiepileptic treatment that can improve the clinical outcomes of the disease.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B68">Orsini et al. 2018</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0E2MBG">IM</abbrev>
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EBNBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1"><italic>CYP2C9</italic> pharmacogenetic testing is recommended as a new strategy for <abbrev xlink:title="valproic acid" id="ABBRID0EKNBG">VPA</abbrev> therapy in childhood. This facilitates optimization of <abbrev xlink:title="valproic acid" id="ABBRID0EONBG">VPA</abbrev> dosing, helping to avoid adverse reactions induced by incorrect dosing, such as abnormal blood levels of ammonia and alkaline phosphatase, and improving the safety of anticonvulsant therapy in children.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B65">Monostory et al. 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2/ CYP2C19*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EBOBG">IM</abbrev>
                  <italic>CYP2C9*3/ CYP2C19*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EHOBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1"><italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and others are potential biomarkers for <abbrev xlink:title="valproic acid" id="ABBRID0ESOBG">VPA</abbrev> and <abbrev xlink:title="carbamazepine" id="ABBRID0EWOBG">CBZ</abbrev> therapy. More pharmacogenetic research and therapeutic drug monitoring studies are required to fully understand the impact on clinical practice.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B46">Iannaccone et al. 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EJPBG">PM</abbrev>
                  <italic>CYP2C19*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EPPBG">IM</abbrev>
                </td>
                <td rowspan="1" colspan="1">Dose adjustment based on <italic>CYP2C9</italic> genotype, especially prior to therapy, would be beneficial to reduce the risk of <abbrev xlink:title="carbamazepine" id="ABBRID0EYPBG">CBZ</abbrev> and <abbrev xlink:title="phenytoin" id="ABBRID0E3PBG">PHT</abbrev> adverse reactions or poisoning.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B1">Ahmed et al. 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EPQBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">High arene oxide concentrations of <abbrev xlink:title="phenytoin" id="ABBRID0EWQBG">PHT</abbrev> increase the probability of <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0E1QBG">SJS</abbrev> and NET.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B35">Fowler et al. 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0ENRBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1"><italic>CYP2C9*3</italic> is significantly associated with higher <abbrev xlink:title="phenytoin" id="ABBRID0EWRBG">PHT</abbrev> concentrations and cutaneous adverse reactions. Prescribing pharmacogenetic testing is suggested to predict <abbrev xlink:title="phenytoin" id="ABBRID0E1RBG">PHT</abbrev>-induced adverse reactions and guide optimal dose selection.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B24">Chang et al. 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0ENSBG">IM</abbrev>
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0ETSBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">The dose of <abbrev xlink:title="phenytoin" id="ABBRID0E1SBG">PHT</abbrev> should be individualized based on the metabolic phenotype to reduce the risk of adverse reactions that could justify its withdrawal, even if it is effective.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B77">Silvado et al. 2018</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0ENTBG">IM</abbrev>
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0ETTBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">It is important to assess the risk of developing adverse reactions induced by <abbrev xlink:title="valproic acid" id="ABBRID0E1TBG">VPA</abbrev> and propose its correction, according to the pharmacogenetic profile of the patient and the serum level of the drug.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B76">Shnayder et al. 2023</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Meta-analysis study</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EQUBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">The <italic>CYP2C9*3</italic> SNP is associated with increased serum levels of <abbrev xlink:title="valproic acid" id="ABBRID0EZUBG">VPA</abbrev>. In patients with epilepsy and <italic>CYP2C9*3</italic> genotype, dose adjustment may be necessary to maintain a serum <abbrev xlink:title="valproic acid" id="ABBRID0E6UBG">VPA</abbrev> level within the therapeutic index.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B100">Yoon et al. 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Systematic review study and meta-analysis</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0EVVBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">There is a significant association between <italic>CYP2C9*3</italic> and <abbrev xlink:title="phenytoin" id="ABBRID0E5VBG">PHT</abbrev>-induced <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0ECWBG">SJS</abbrev>/NE, especially in a Thai population. <italic>CYP2C9*3</italic> is a predictive genetic biomarker of <abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EIWBG">SJS</abbrev>/NE induced by <abbrev xlink:title="phenytoin" id="ABBRID0EMWBG">PHT</abbrev>.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B97">Wu et al. 2018</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Meta-analysis study</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*3</italic>
                  <abbrev xlink:title="poor metabolizer" id="ABBRID0ECXBG">PM</abbrev>
                </td>
                <td rowspan="1" colspan="1">Assessment of <italic>CYP2C9</italic> and HLA risk alleles are predictive genetic tests to prevent <abbrev xlink:title="phenytoin" id="ABBRID0ELXBG">PHT</abbrev> hypersensitivity in Asians.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B85">Su et al. 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Systematic review study and meta-analysis</td>
                <td rowspan="1" colspan="1">
                  <italic>CYP2C9*2/ CYP2C19*2</italic>
                  <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EBYBG">IM</abbrev>
                </td>
                <td rowspan="1" colspan="1">Dosage for patients with <abbrev xlink:title="intermediate metabolizer" id="ABBRID0EIYBG">IM</abbrev><italic>CYP2C9</italic> phenotype should be lower (2.1 to 3.4 mg/kg/day) to achieve therapeutic <abbrev xlink:title="phenytoin" id="ABBRID0EOYBG">PHT</abbrev> levels.</td>
                <td rowspan="1" colspan="1">(<xref ref-type="bibr" rid="B50">Kanjanasilp et al. 2021</xref>)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p><abbrev xlink:title="normal metabolizer" id="ABBRID0E5YBG">NM</abbrev>: normal metabolizer; <abbrev xlink:title="intermediate metabolizer" id="ABBRID0ECZBG">IM</abbrev>: intermediate metabolizer; <abbrev xlink:title="poor metabolizer" id="ABBRID0EGZBG">PM</abbrev>: poor metabolizer; <abbrev xlink:title="valproic acid" id="ABBRID0EKZBG">VPA</abbrev>: valproic acid; <abbrev xlink:title="carbamazepine" id="ABBRID0EOZBG">CBZ</abbrev>: carbamazepine; <abbrev xlink:title="phenytoin" id="ABBRID0ESZBG">PHT</abbrev>: phenytoin.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Fig. <xref ref-type="fig" rid="F4">4</xref> summarizes the clinical implications of the <italic>CYP2C9</italic> and <italic>CYP2C19</italic><abbrev xlink:title="single nucleotide polymorphisms" id="ABBRID0EA1BG">SNPs</abbrev> on the serum levels of valproic acid, carbamazepine, and phenytoin.</p>
        <fig id="F4" position="float" orientation="portrait">
          <object-id content-type="doi">10.3897/pharmacia.70.e109011.figure4</object-id>
          <object-id content-type="arpha">B631DA15-137E-517D-AB80-B56A43CB8F62</object-id>
          <label>Figure 4.</label>
          <caption>
            <p>Location of <italic>CYP2C9/CYP2C19</italic> genes, allelic variants and clinical implication.</p>
          </caption>
          <graphic xlink:href="pharmacia-70-e109011-g004.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_892758.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/892758</uri>
          </graphic>
        </fig>
        <p>In parts A and B, it can be seen that the <italic>CYP2C9</italic> gene is located in locus 10q24 of chromosome 10 (long arm of chromosome 10 in region 24) and encodes its respective CYP2C9 enzyme; the curve of serum concentration vs. time of a normal metabolizer (<abbrev xlink:title="normal metabolizers" id="ABBRID0EX1BG">NM</abbrev>) whose concentration is within the therapeutic index is observed; allelic variants <italic>CYP2C9*2</italic>, <italic>CYP2C9*3</italic>, <italic>CYP2C19*2</italic>, and <italic>CYP2C19*3</italic> are implicated in the poor metabolizer (<abbrev xlink:title="poor metabolizer" id="ABBRID0ED2BG">PM</abbrev>) phenotype, in which case the serum valproic acid (<abbrev xlink:title="valproic acid" id="ABBRID0EH2BG">VPA</abbrev>) concentration level exceeds the trough toxic concentration (CMT) of 100 mg/L and induces hyperammonemia (A); in part B it is observed that the serum level curve of phenytoin is greater than 20 mg/L; and the allelic variants <italic>CYP2C9*2</italic> and <italic>CYP2C9*3</italic>, are associated with Stevens-Johnson syndrome (<abbrev xlink:title="Stevens-Johnson syndrome" id="ABBRID0EP2BG">SJS</abbrev>) and toxic epidermal necrolysis (<abbrev xlink:title="epidermal necrolysis" id="ABBRID0ET2BG">TEN</abbrev>). Part C shows that the <italic>CYP2C19</italic> gene is located in the 10q24.1 locus of chromosome 10 and encodes its respective CYP2C19 enzyme; the curve of serum concentration vs time of a normal metabolizer (<abbrev xlink:title="normal metabolizers" id="ABBRID0EZ2BG">NM</abbrev>) and the curve of serum concentration vs time that exceeds the C<sub>MT</sub> of 12 mg/L in a <abbrev xlink:title="poor metabolizer" id="ABBRID0E62BG">PM</abbrev>, and the allelic variants <italic>CYP2C9*2</italic>, <italic>CYP2C9*3</italic>, <italic>CYP2C19*2</italic> and <italic>CYP2C19*3</italic> associated with cutaneous adverse reactions induced by carbamazepine (<abbrev xlink:title="carbamazepine" id="ABBRID0EL3BG">CBZ</abbrev>). Figure made by the authors.</p>
        <p>The results of this review must be considered in the context of various limitations. The main one is in the scant literature published in Peru. Other biases that can lead to confusion is to include various observational, analytical, review, systematic, and meta-analysis studies, and not only consider studies with rigorous statistical analysis; however, this review should be considered as a contribution to science and to promote studies in pharmacogenetics and precision medicine in Peru.</p>
      </sec>
    </sec>
    <sec sec-type="﻿Conclusions and future perspectives" id="SECID0EQ3BG">
      <title>﻿Conclusions and future perspectives</title>
      <p>Based on the review of the scientific literature, it is concluded that <italic>CYP2C9*2</italic>, <italic>CYP2C9*3</italic>, <italic>CYP2C19*2</italic>, and <italic>CYP2C19*3</italic> single nucleotide polymorphisms may have a clinical impact on valproic acid, carbamazepine, and phenytoin therapy. There is more evidence of a significant association between <italic>CYP2C9*3</italic> and the adverse reactions induced by phenytoin; <italic>CYP2C9*3</italic> being proposed as a predictive genetic biomarker of Stevens-Johnson syndrome and epidermal necrolysis induced by the aforementioned drug.</p>
      <p>In the short term, more multicenter studies and large prospective observational studies of pharmacogenetics in patients with epilepsy are required before starting treatment, to evaluate the association between genes, high serum levels and adverse drug reactions.</p>
      <p>The review studies will form part of the scientific evidence, so that it can be done in the future analytical observational studies (cases/controls and cohorts) and randomized clinical trials (<abbrev xlink:title="randomized clinical trials" id="ABBRID0EF4BG">RCTs</abbrev>) of pharmacogenetics will be carried out, which will allow the implementation of precision medicine in the delivery systems health of Peru and will be a routine clinical practice that contributes to improving the quality of life of patients.</p>
    </sec>
    <sec sec-type="﻿Comment" id="SECID0EJ4BG">
      <title>﻿Comment</title>
      <p>We hope that this review study will be considered as a valuable tool to individualize the dose of drugs, at the same time, give sustainability to medical care and Pharmacotherapeutic Follow-up in the Clinical Pharmacy of Peru.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>﻿Reference</title>
      <ref id="B1">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ahmed</surname><given-names>AF</given-names></name><name name-style="western"><surname>Sukasem</surname><given-names>C</given-names></name><name name-style="western"><surname>Sabbah</surname><given-names>MA</given-names></name><name name-style="western"><surname>Musa</surname><given-names>NF</given-names></name><name name-style="western"><surname>Mohamed Noor</surname><given-names>DA</given-names></name><name name-style="western"><surname>Daud</surname><given-names>NAA</given-names></name></person-group> (<year>2021</year>) Genetic determinants in HLA and cytochrome P450 genes in the risk of aromatic antiepileptic-induced severe cutaneous adverse reactions. Journal of Personalized Medicine 11(5): e383. <ext-link xlink:href="10.3390/jpm11050383" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/jpm11050383</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Aldaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferriols</surname><given-names>R</given-names></name><name name-style="western"><surname>Aumente</surname><given-names>D</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>MV</given-names></name><name name-style="western"><surname>Farré</surname><given-names>S</given-names></name><name name-style="western"><surname>García</surname><given-names>B</given-names></name><name name-style="western"><surname>Marqués</surname><given-names>R</given-names></name><name name-style="western"><surname>Mash</surname><given-names>P</given-names></name><name name-style="western"><surname>Porta</surname><given-names>B</given-names></name><name name-style="western"><surname>Outeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Soja</surname><given-names>D</given-names></name></person-group> (<year>2011</year>) <article-title>Monitorización farmacocinética de antiepilépticos.</article-title><source>Farmacia Hospitalaria</source><volume>35</volume>(<issue>6</issue>): <fpage>326</fpage>–<lpage>339</lpage>. <ext-link xlink:href="10.1016/j.farma.2010.10.005" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.farma.2010.10.005</ext-link></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Loja</surname><given-names>B</given-names></name><name name-style="western"><surname>Miyasato</surname><given-names>JM</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cerro</surname><given-names>RA</given-names></name><name name-style="western"><surname>Quiñones</surname><given-names>LA</given-names></name><name name-style="western"><surname>Varela</surname><given-names>NM</given-names></name></person-group> (<year>2019</year>) <article-title>Estudio de las variantes alélicas <italic>CYP2C9*2</italic> y <italic>CYP2C9*3</italic> en muestras de población mestiza peruana.</article-title><source>Biomedica</source><volume>39</volume>(<issue>3</issue>): <fpage>601</fpage>–<lpage>610</lpage>. <ext-link xlink:href="10.7705/biomedica.4636" ext-link-type="doi" xlink:type="simple">https://doi.org/10.7705/biomedica.4636</ext-link></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Ybañez-Julca</surname><given-names>R</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Tejada-Bechi</surname><given-names>C</given-names></name><name name-style="western"><surname>Cerro</surname><given-names>R</given-names></name><name name-style="western"><surname>Quiñones</surname><given-names>LA</given-names></name><name name-style="western"><surname>Varela</surname><given-names>N</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>CA</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>E</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>MR</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name></person-group> (<year>2021a</year>) <article-title>Frequency of <italic>CYP2D6*3</italic> and *<italic>4</italic> and metabolizer phenotypes in three mestizo Peruvian populations.</article-title><source>Pharmacia</source><volume>68</volume>(<issue>4</issue>): <fpage>891</fpage>–<lpage>898</lpage>. <ext-link xlink:href="10.3897/pharmacia.68.e75165" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3897/pharmacia.68.e75165</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>MR</given-names></name><name name-style="western"><surname>Palomino-Jhong</surname><given-names>JJ</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>CA</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>EA</given-names></name><name name-style="western"><surname>Ochoa-Pachas</surname><given-names>G</given-names></name><name name-style="western"><surname>Pineda-Pérez</surname><given-names>M</given-names></name><name name-style="western"><surname>Bolarte</surname><given-names>M</given-names></name></person-group> (<year>2021b</year>) <article-title><italic>In vitro</italic> biopharmaceutical equivalence of Carbamazepine sodium tablets available in Lima, Peru.</article-title><source>Dissolution Technologies</source><volume>28</volume>(<issue>2</issue>): <fpage>1</fpage>–<lpage>10</lpage>. <ext-link xlink:href="10.14227/DT280221PGC2" ext-link-type="doi" xlink:type="simple">https://doi.org/10.14227/DT280221PGC2</ext-link></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>M</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name><name name-style="western"><surname>Palomino-Jhong</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ochoa-Pachas</surname><given-names>G</given-names></name><name name-style="western"><surname>Chonn-Chang</surname><given-names>A</given-names></name><name name-style="western"><surname>Sullon-Dextre</surname><given-names>L</given-names></name><name name-style="western"><surname>Loja-Herrera</surname><given-names>B</given-names></name><name name-style="western"><surname>Pineda-Perez</surname><given-names>M</given-names></name></person-group> (<year>2021c</year>) <article-title><italic>In vitro</italic> biopharmaceutical equivalence of 5-mg glibenclamide tablets in simulated intestinal fluid without enzymes.</article-title><source>Dissolution Technologies</source><volume>28</volume>(<issue>1</issue>): <fpage>1</fpage>–<lpage>12</lpage>. <ext-link xlink:href="10.14227/DT280121PGC2" ext-link-type="doi" xlink:type="simple">https://doi.org/10.14227/DT280121PGC2</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>A</given-names></name><name name-style="western"><surname>García</surname><given-names>G</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A</given-names></name><name name-style="western"><surname>Gustavo Paredes</surname><given-names>G</given-names></name><name name-style="western"><surname>Mora</surname><given-names>M</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pariona</surname><given-names>R</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>MR</given-names></name><name name-style="western"><surname>Chávez</surname><given-names>H</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name><name name-style="western"><surname>Laos-Anchante</surname><given-names>DL</given-names></name><name name-style="western"><surname>Loja-Herrera</surname><given-names>B</given-names></name><name name-style="western"><surname>Bolarte-Arteaga</surname><given-names>M</given-names></name><name name-style="western"><surname>Mario Pineda</surname><given-names>M</given-names></name></person-group> (<year>2022a</year>) <article-title>Phenytoin concentration in people with epilepsy: a comparative study in serum and saliva.</article-title><source>Pharmacia</source><volume>69</volume>(<issue>3</issue>): <fpage>809</fpage>–<lpage>814</lpage>. <ext-link xlink:href="10.3897/pharmacia.69.e87168" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3897/pharmacia.69.e87168</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>G</given-names></name><name name-style="western"><surname>García</surname><given-names>G</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Saravia</surname><given-names>M</given-names></name><name name-style="western"><surname>Losno</surname><given-names>R</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>MR</given-names></name><name name-style="western"><surname>Chávez</surname><given-names>H</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>M</given-names></name><name name-style="western"><surname>Sullón-Dextre</surname><given-names>L</given-names></name></person-group> (<year>2022b</year>) <article-title>Serum monitoring of carbamazepine in patients with epilepsy and clinical implications.</article-title><source>Pharmacia</source><volume>69</volume>(<issue>2</issue>): <fpage>401</fpage>–<lpage>406</lpage>. <ext-link xlink:href="10.3897/pharmacia.69.e82425" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3897/pharmacia.69.e82425</ext-link></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Cotuá</surname><given-names>J</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>M</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>MR</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name><name name-style="western"><surname>Laos-Anchante</surname><given-names>D</given-names></name><name name-style="western"><surname>Surco-Laos</surname><given-names>F</given-names></name><name name-style="western"><surname>Loja</surname><given-names>B</given-names></name><name name-style="western"><surname>Bolarte-Arteaga</surname><given-names>M</given-names></name><name name-style="western"><surname>Pineda-Pérez</surname><given-names>M</given-names></name></person-group> (<year>2022c</year>) <article-title>Serum concentrations of valproic acid in people with epilepsy: Clinical implication.</article-title><source>Journal of Pharmacy &amp; Pharmacognosy Research</source><volume>10</volume>(<issue>6</issue>): <fpage>1117</fpage>–<lpage>1125</lpage>. <ext-link xlink:href="10.56499/jppres22.1500_10.6.1117" ext-link-type="doi" xlink:type="simple">https://doi.org/10.56499/jppres22.1500_10.6.1117</ext-link></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Miyasato</surname><given-names>JM</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>EA</given-names></name><name name-style="western"><surname>Loja</surname><given-names>B</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>L</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>M</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>M</given-names></name><name name-style="western"><surname>Palomino-Jhong</surname><given-names>JJ</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name></person-group> (<year>2020</year>) <article-title><italic>In vitro</italic> therapeutic equivalence of two multisource (generic) formulations of sodium phenytoin (100 mg) available in Peru.</article-title><source>Dissolution Technologies</source><volume>27</volume>(<issue>4</issue>): <fpage>33</fpage>–<lpage>40</lpage>. <ext-link xlink:href="10.14227/DT270420P33" ext-link-type="doi" xlink:type="simple">https://doi.org/10.14227/DT270420P33</ext-link></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name><name name-style="western"><surname>Saravia</surname><given-names>M</given-names></name><name name-style="western"><surname>Losno</surname><given-names>R</given-names></name><name name-style="western"><surname>Pariona</surname><given-names>R</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ybañez-Julca</surname><given-names>RO</given-names></name><name name-style="western"><surname>Loja</surname><given-names>B</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>MR</given-names></name><name name-style="western"><surname>García</surname><given-names>JA</given-names></name><name name-style="western"><surname>Surco-Laos</surname><given-names>F</given-names></name><name name-style="western"><surname>Laos-Anchante</surname><given-names>D</given-names></name><name name-style="western"><surname>Chávez</surname><given-names>H</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>P</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>M</given-names></name></person-group> (<year>2023</year>) <article-title><italic>CYP2D6</italic> and <italic>CYP2C19</italic> genes associated with tricontinental and latin American ancestry of peruvians.</article-title><source>Drug Metabolism and Bioanalysis Letters</source><volume>16</volume>(<issue>1</issue>): <fpage>14</fpage>–<lpage>26</lpage>. <ext-link xlink:href="10.2174/1872312815666221213151140" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2174/1872312815666221213151140</ext-link></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Balestrini</surname><given-names>S</given-names></name><name name-style="western"><surname>Sisodiya</surname><given-names>SM</given-names></name></person-group> (<year>2018</year>) <article-title>Pharmacogenomics in epilepsy.</article-title><source>Neuroscience Letters</source><volume>667</volume>: <fpage>27</fpage>–<lpage>39</lpage>. <ext-link xlink:href="10.1016/j.neulet.2017.01.014" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.neulet.2017.01.014</ext-link></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Bartra</surname><given-names>M</given-names></name><name name-style="western"><surname>Losno</surname><given-names>R</given-names></name><name name-style="western"><surname>Valderrama-Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>Muñoz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bendezú</surname><given-names>M</given-names></name><name name-style="western"><surname>García</surname><given-names>J</given-names></name><name name-style="western"><surname>Surco</surname><given-names>F</given-names></name><name name-style="western"><surname>Basurto</surname><given-names>P</given-names></name><name name-style="western"><surname>Pineda-Pérez</surname><given-names>M</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>AT</given-names></name></person-group> (<year>2021</year>) Interacciones farmacocinéticas de la azitromicina e implicación clínica. Revista Cubana de Medicina Militar 50(3): e02101284.</mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Beitelshees</surname><given-names>AL</given-names></name><name name-style="western"><surname>Horenstein</surname><given-names>RB</given-names></name><name name-style="western"><surname>Vesely</surname><given-names>MR</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>MR</given-names></name><name name-style="western"><surname>Shuldiner</surname><given-names>AR</given-names></name></person-group> (<year>2011</year>) <article-title>Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>89</volume>(<issue>3</issue>): <fpage>455</fpage>–<lpage>459</lpage>. <ext-link xlink:href="10.1038/clpt.2010.316" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/clpt.2010.316</ext-link></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Bousman</surname><given-names>CA</given-names></name><name name-style="western"><surname>Menke</surname><given-names>A</given-names></name><name name-style="western"><surname>Müller</surname><given-names>DJ</given-names></name></person-group> (<year>2019</year>) <article-title>Towards pharmacogenetic-based treatment in psychiatry.</article-title><source>Journal of Neural Transmission</source><volume>126</volume>(<issue>1</issue>): <fpage>1</fpage>–<lpage>3</lpage>. <ext-link xlink:href="10.1007/s00702-018-01968-9" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s00702-018-01968-9</ext-link></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Brandolese</surname><given-names>R</given-names></name><name name-style="western"><surname>Scordo</surname><given-names>MG</given-names></name><name name-style="western"><surname>Spina</surname><given-names>E</given-names></name><name name-style="western"><surname>Gusella</surname><given-names>M</given-names></name><name name-style="western"><surname>Padrini</surname><given-names>R</given-names></name></person-group> (<year>2001</year>) <article-title>Severe phenytoin intoxication in a subject homozygous for <italic>CYP2C9*3</italic>.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>70</volume>(<issue>4</issue>): <fpage>391</fpage>–<lpage>394</lpage>. <ext-link xlink:href="10.1067/mcp.2001.118868" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1067/mcp.2001.118868</ext-link></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Burneo</surname><given-names>JG</given-names></name><name name-style="western"><surname>Steven</surname><given-names>DA</given-names></name><name name-style="western"><surname>Arango</surname><given-names>M</given-names></name><name name-style="western"><surname>Zapata</surname><given-names>W</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>CM</given-names></name><name name-style="western"><surname>Becerra</surname><given-names>A</given-names></name></person-group> (<year>2017</year>) <article-title>La cirugía de epilepsia y el establecimiento de programas quirúrgicos en el Perú: El proyecto de colaboración entre Perú y Canadá.</article-title><source>Revista de Neuro-Psiquiatría</source><volume>80</volume>(<issue>3</issue>): <fpage>181</fpage>–<lpage>188</lpage>. <ext-link xlink:href="10.20453/rnp.v80i3.3155" ext-link-type="doi" xlink:type="simple">https://doi.org/10.20453/rnp.v80i3.3155</ext-link></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Burneo</surname><given-names>JG</given-names></name><name name-style="western"><surname>Tellez-Zenteno</surname><given-names>J</given-names></name><name name-style="western"><surname>Wiebe</surname><given-names>S</given-names></name></person-group> (<year>2005</year>) <article-title>Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence.</article-title><source>Epilepsy Research</source><volume>66</volume>(<issue>1–3</issue>): <fpage>63</fpage>–<lpage>74</lpage>. <ext-link xlink:href="10.1016/j.eplepsyres.2005.07.002" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.eplepsyres.2005.07.002</ext-link></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Caudle</surname><given-names>KE</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>AE</given-names></name><name name-style="western"><surname>Whirl-Carrillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>LH</given-names></name><name name-style="western"><surname>Mintzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MTM</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name><name name-style="western"><surname>Callaghan</surname><given-names>JT</given-names></name></person-group> (<year>2014</year>) <article-title>Clinical pharmacogenetics implementation consortium guidelines for <italic>CYP2C9</italic> and <italic>HLA-B</italic> genotypes and phenytoin dosing.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>96</volume>(<issue>5</issue>): <fpage>542</fpage>–<lpage>548</lpage>. <ext-link xlink:href="10.1038/clpt.2014.159" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/clpt.2014.159</ext-link></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Céspedes-Garro</surname><given-names>C</given-names></name><name name-style="western"><surname>Fricke-Galindo</surname><given-names>I</given-names></name><name name-style="western"><surname>Naranjo</surname><given-names>ME</given-names></name><name name-style="western"><surname>Rodrigues-Soares</surname><given-names>F</given-names></name><name name-style="western"><surname>Fariñas</surname><given-names>H</given-names></name><name name-style="western"><surname>de Andrés</surname><given-names>F</given-names></name><name name-style="western"><surname>López-López</surname><given-names>M</given-names></name><name name-style="western"><surname>Peñas-Lledó</surname><given-names>EM</given-names></name><name name-style="western"><surname>LLerena</surname><given-names>A</given-names></name></person-group> (<year>2015</year>) <article-title>Worldwide interethnic variability and geographical distribution of <italic>CYP2C9</italic> genotypes and phenotypes.</article-title><source>Expert Opinion on Drug Metabolism &amp; Toxicology</source><volume>11</volume>(<issue>12</issue>): <fpage>1893</fpage>–<lpage>1905</lpage>. <ext-link xlink:href="10.1517/17425255.2015.1111871" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1517/17425255.2015.1111871</ext-link></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Chadwick</surname><given-names>DW</given-names></name></person-group> (<year>1985</year>) <article-title>Concentration-effect relationships of valproic acid.</article-title><source>Clinical Pharmacokinetics</source><volume>10</volume>(<issue>2</issue>): <fpage>155</fpage>–<lpage>163</lpage>. <ext-link xlink:href="10.2165/00003088-198510020-00003" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2165/00003088-198510020-00003</ext-link></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Chaudhry</surname><given-names>AS</given-names></name><name name-style="western"><surname>Urban</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Lamba</surname><given-names>JK</given-names></name><name name-style="western"><surname>Birnbaum</surname><given-names>AK</given-names></name><name name-style="western"><surname>Remmel</surname><given-names>RP</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>M</given-names></name><name name-style="western"><surname>Strom</surname><given-names>S</given-names></name><name name-style="western"><surname>You</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kasperaviciute</surname><given-names>D</given-names></name><name name-style="western"><surname>Catarino</surname><given-names>CB</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sisodiya</surname><given-names>SM</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>DB</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>EG</given-names></name></person-group> (<year>2010</year>) <article-title><italic>CYP2C9*1B</italic> promoter polymorphisms, in linkage with <italic>CYP2C19*2</italic>, affect phenytoin autoinduction of clearance and maintenance dose.</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>332</volume>(<issue>2</issue>): <fpage>599</fpage>–<lpage>611</lpage>. <ext-link xlink:href="10.1124/jpet.109.161026" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1124/jpet.109.161026</ext-link></mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Chaudhry</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kochhar</surname><given-names>R</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>KK</given-names></name></person-group> (<year>2008</year>) <article-title>Genetic polymorphism of CYP2C19 &amp; therapeutic response to proton pump inhibitors.</article-title><source>Indian Journal of Medical Research</source><volume>127</volume>(<issue>6</issue>): <fpage>521</fpage>–<lpage>530</lpage>.</mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Chang</surname><given-names>WC</given-names></name><name name-style="western"><surname>Hung</surname><given-names>SI</given-names></name><name name-style="western"><surname>Carleton</surname><given-names>BC</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WH</given-names></name></person-group> (<year>2020</year>) <article-title>An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.</article-title><source>Expert Opinion on Drug Metabolism &amp; Toxicology</source><volume>16</volume>(<issue>8</issue>): <fpage>723</fpage>–<lpage>734</lpage>. <ext-link xlink:href="10.1080/17425255.2020.1780209" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1080/17425255.2020.1780209</ext-link></mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Chbili</surname><given-names>C</given-names></name><name name-style="western"><surname>Hassine</surname><given-names>A</given-names></name><name name-style="western"><surname>Laouani</surname><given-names>A</given-names></name><name name-style="western"><surname>Amor</surname><given-names>SB</given-names></name><name name-style="western"><surname>Nouira</surname><given-names>M</given-names></name><name name-style="western"><surname>Ammou</surname><given-names>SB</given-names></name><name name-style="western"><surname>Saguem</surname><given-names>S</given-names></name></person-group> (<year>2017</year>) <article-title>The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients.</article-title><source>Archives of Medical Science</source><volume>13</volume>(<issue>2</issue>): <fpage>353</fpage>–<lpage>360</lpage>. <ext-link xlink:href="10.5114/aoms.2016.60090" ext-link-type="doi" xlink:type="simple">https://doi.org/10.5114/aoms.2016.60090</ext-link></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Chen</surname><given-names>PY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Polonia</surname><given-names>RE</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KM</given-names></name></person-group> (<year>2009</year>) <article-title>Biological variations in depression and anxiety between east and west.</article-title><source>CNS Neuroscience &amp; Therapeutics</source><volume>15</volume>(<issue>3</issue>): <fpage>283</fpage>–<lpage>294</lpage>. <ext-link xlink:href="10.1111/j.1755-5949.2009.00093.x" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/j.1755-5949.2009.00093.x</ext-link></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Chung</surname><given-names>JY</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JR</given-names></name><name name-style="western"><surname>Lim</surname><given-names>KS</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>DR</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SG</given-names></name><name name-style="western"><surname>Jang</surname><given-names>IJ</given-names></name></person-group> (<year>2008</year>) <article-title>Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to <italic>UGT2B7</italic> genetic polymorphism in healthy subjects.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>83</volume>(<issue>4</issue>): <fpage>595</fpage>–<lpage>600</lpage>. <ext-link xlink:href="10.1038/sj.clpt.6100324" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/sj.clpt.6100324</ext-link></mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Claudio-Campos</surname><given-names>K</given-names></name><name name-style="western"><surname>Labastida</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>A</given-names></name><name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name><name name-style="western"><surname>Renta-Torres</surname><given-names>J</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>D</given-names></name><name name-style="western"><surname>Rivera-Miranda</surname><given-names>G</given-names></name><name name-style="western"><surname>Scott</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ruaño</surname><given-names>G</given-names></name><name name-style="western"><surname>Cadilla</surname><given-names>CL</given-names></name><name name-style="western"><surname>Duconge-Soler</surname><given-names>J</given-names></name></person-group> (<year>2017</year>) Warfarin anticoagulation therapy in Caribbean Hispanics of Puerto Rico: A candidate gene association study. Frontiers in Pharmacology 8: e347. <ext-link xlink:href="10.3389/fphar.2017.00347" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3389/fphar.2017.00347</ext-link></mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Darwish</surname><given-names>M</given-names></name><name name-style="western"><surname>Bond</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Hellriegel</surname><given-names>ET</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>P</given-names></name></person-group> (<year>2015</year>) <article-title>Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults.</article-title><source>Clinical Therapeutics</source><volume>37</volume>(<issue>2</issue>): <fpage>325</fpage>–<lpage>337</lpage>. <ext-link xlink:href="10.1016/j.clinthera.2014.09.014" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.clinthera.2014.09.014</ext-link></mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Dehbozorgi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamalidehghan</surname><given-names>B</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>I</given-names></name><name name-style="western"><surname>Dehghanfard</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sangtarash</surname><given-names>MH</given-names></name><name name-style="western"><surname>Firoozi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahmadipour</surname><given-names>F</given-names></name><name name-style="western"><surname>Meng</surname><given-names>GY</given-names></name><name name-style="western"><surname>Houshmand</surname><given-names>M</given-names></name></person-group> (<year>2018</year>) <article-title>Prevalence of the <italic>CYP2C19*2</italic> (681 G&gt;A), *<italic>3</italic> (636 G&gt;A) and *<italic>17</italic> (‑806 C&gt;T) alleles among an Iranian population of different ethnicities.</article-title><source>Molecular Medicine Reports</source><volume>17</volume>(<issue>3</issue>): <fpage>4195</fpage>–<lpage>4202</lpage>. <ext-link xlink:href="10.3892/mmr.2018.8377" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3892/mmr.2018.8377</ext-link></mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Doré</surname><given-names>M</given-names></name><name name-style="western"><surname>San Juan</surname><given-names>AE</given-names></name><name name-style="western"><surname>Frenette</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D</given-names></name></person-group> (<year>2017</year>) <article-title>Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia.</article-title><source>Pharmacotherapy</source><volume>37</volume>(<issue>8</issue>): <fpage>900</fpage>–<lpage>907</lpage>. <ext-link xlink:href="10.1002/phar.1965" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/phar.1965</ext-link><ext-link xlink:href="10.1002/phar.1965" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/phar.1965</ext-link></mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Fisher</surname><given-names>RS</given-names></name><name name-style="western"><surname>Cross</surname><given-names>JH</given-names></name><name name-style="western"><surname>French</surname><given-names>JA</given-names></name><name name-style="western"><surname>Higurashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>E</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>FE</given-names></name><name name-style="western"><surname>Lagae</surname><given-names>L</given-names></name><name name-style="western"><surname>Moshé</surname><given-names>SL</given-names></name><name name-style="western"><surname>Peltola</surname><given-names>J</given-names></name><name name-style="western"><surname>Roulet Perez</surname><given-names>E</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>IE</given-names></name><name name-style="western"><surname>Zuberi</surname><given-names>SM</given-names></name></person-group> (<year>2017</year>) <article-title>Operational classification of seizure types by the International League Against Epilepsy: Position paper of the ILAE commission for classification and terminology.</article-title><source>Epilepsia</source><volume>58</volume>(<issue>4</issue>): <fpage>522</fpage>–<lpage>530</lpage>. <ext-link xlink:href="10.1111/epi.13670" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/epi.13670</ext-link></mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Fricke-Galindo</surname><given-names>I</given-names></name><name name-style="western"><surname>Jung-Cook</surname><given-names>H</given-names></name><name name-style="western"><surname>Llerena</surname><given-names>A</given-names></name><name name-style="western"><surname>López-López</surname><given-names>M</given-names></name></person-group> (<year>2018</year>) <article-title>Farmacogenética de reacciones adversas a fármacos antiepilépticos.</article-title><source>Revue Neurologique</source><volume>33</volume>(<issue>3</issue>): <fpage>165</fpage>–<lpage>176</lpage>. <ext-link xlink:href="10.1016/j.nrl.2015.03.005" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.nrl.2015.03.005</ext-link></mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Fohner</surname><given-names>AE</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>AE</given-names></name><name name-style="western"><surname>Thai</surname><given-names>KK</given-names></name><name name-style="western"><surname>Ranatunga</surname><given-names>DK</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>BL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>VX</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>CA</given-names></name></person-group> (<year>2020</year>) <article-title>Associations of CYP2C9 and CYP2C19 pharmacogenetic variation with phenytoin-induced cutaneous adverse drug reactions.</article-title><source>Clinical and Translational Science</source><volume>13</volume>(<issue>5</issue>): <fpage>1004</fpage>–<lpage>1009</lpage>. <ext-link xlink:href="10.1111/cts.12787" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/cts.12787</ext-link></mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Fowler</surname><given-names>T</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>AS</given-names></name><name name-style="western"><surname>Lozsádi</surname><given-names>D</given-names></name></person-group> (<year>2019</year>) <article-title>Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting.</article-title><source>Seizure</source><volume>72</volume>: <fpage>61</fpage>–<lpage>70</lpage>. <ext-link xlink:href="10.1016/j.seizure.2019.07.003" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.seizure.2019.07.003</ext-link></mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Garg</surname><given-names>VK</given-names></name><name name-style="western"><surname>Supriya</surname></name><name name-style="western"><surname>Shree</surname><given-names>R</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>A</given-names></name><name name-style="western"><surname>Takkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Khullar</surname><given-names>M</given-names></name><name name-style="western"><surname>Saikia</surname><given-names>B</given-names></name><name name-style="western"><surname>Medhi</surname><given-names>B</given-names></name><name name-style="western"><surname>Modi</surname><given-names>M</given-names></name></person-group> (<year>2022</year>) <article-title>Genetic abnormality of cytochrome-<italic>P2C9*3</italic> allele predisposes to epilepsy and phenytoin-induced adverse drug reactions: genotyping findings of cytochrome-alleles in the North Indian population.</article-title><source>Future Journal of Pharmaceutical Sciences</source><volume>8</volume>(<issue>44</issue>): <fpage>1</fpage>–<lpage>8</lpage>. <ext-link xlink:href="10.1186/s43094-022-00432-6" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1186/s43094-022-00432-6</ext-link></mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Gawrońska-Szklarz</surname><given-names>B</given-names></name><name name-style="western"><surname>Adamiak-Giera</surname><given-names>U</given-names></name><name name-style="western"><surname>Wyska</surname><given-names>E</given-names></name><name name-style="western"><surname>Kurzawski</surname><given-names>M</given-names></name><name name-style="western"><surname>Gornik</surname><given-names>W</given-names></name><name name-style="western"><surname>Kaldonska</surname><given-names>M</given-names></name><name name-style="western"><surname>Drozdzik</surname><given-names>M</given-names></name></person-group> (<year>2012</year>) <article-title><italic>CYP2C19</italic> polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.</article-title><source>European Journal of Clinical Pharmacology</source><volume>68</volume>: <fpage>1267</fpage>–<lpage>1274</lpage>. <ext-link xlink:href="10.1007/s00228-012-1252-3" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s00228-012-1252-3</ext-link></mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ghodke-Puranik</surname><given-names>Y</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>CF</given-names></name><name name-style="western"><surname>Lamba</surname><given-names>JK</given-names></name><name name-style="western"><surname>Stevenf</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Birnbaum</surname><given-names>AK</given-names></name><name name-style="western"><surname>Altman</surname><given-names>RB</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name></person-group> (<year>2013</year>) <article-title>Valproic acid pathway: pharmacokinetics and pharmacodynamics.</article-title><source>Pharmacogenet Genomics</source><volume>23</volume>(<issue>4</issue>): <fpage>236</fpage>–<lpage>241</lpage>. <ext-link xlink:href="10.1097/FPC.0b013e32835ea0b2" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1097/FPC.0b013e32835ea0b2</ext-link></mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Gierbolini</surname><given-names>J</given-names></name><name name-style="western"><surname>Giarratano</surname><given-names>M</given-names></name><name name-style="western"><surname>Benbadis</surname><given-names>S</given-names></name></person-group> (<year>2016</year>) <article-title>Carbamazepine-related antiepileptic drugs for the treatment of epilepsy-a comparative review.</article-title><source>Expert Opinion on Pharmacotherapy</source><volume>17</volume>(<issue>7</issue>): <fpage>885</fpage>–<lpage>893</lpage>. <ext-link xlink:href="10.1517/14656566.2016.1168399" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1517/14656566.2016.1168399</ext-link></mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Guk</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SG</given-names></name><name name-style="western"><surname>Chae</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name></person-group> (<year>2019</year>) <article-title>Optimal dosing regimen of phenytoin for Korean epilepsy patients: from premature babies to the elderly.</article-title><source>Journal of Pharmaceutical Sciences</source><volume>108</volume>(<issue>8</issue>): <fpage>2765</fpage>–<lpage>2773</lpage>. <ext-link xlink:href="10.1016/j.xphs.2019.03.022" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.xphs.2019.03.022</ext-link></mixed-citation>
      </ref>
      <ref id="B41">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Hamdy</surname><given-names>SI</given-names></name><name name-style="western"><surname>Hiratsuka</surname><given-names>M</given-names></name><name name-style="western"><surname>Narahara</surname><given-names>K</given-names></name><name name-style="western"><surname>El-Enany</surname><given-names>M</given-names></name><name name-style="western"><surname>Moursi</surname><given-names>N</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>MSE</given-names></name><name name-style="western"><surname>Mizugaki</surname><given-names>M</given-names></name></person-group> (<year>2002</year>) <article-title>Allele and genotype frequencies of polymorphic cytochromes P450 (<italic>CYP2C9</italic>, <italic>CYP2C19</italic>, <italic>CYP2E1</italic>) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.</article-title><source>British Journal of Clinical Pharmacology</source><volume>53</volume>(<issue>6</issue>): <fpage>596</fpage>–<lpage>603</lpage>. <ext-link xlink:href="10.1046/j.1365-2125.2002.01604.x" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1046/j.1365-2125.2002.01604.x</ext-link></mixed-citation>
      </ref>
      <ref id="B42">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Henderson</surname><given-names>LM</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>RF</given-names></name><name name-style="western"><surname>Ray</surname><given-names>L</given-names></name><name name-style="western"><surname>Khan</surname><given-names>BA</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Dillard</surname><given-names>DA</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>BD</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>M</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>PL</given-names></name><name name-style="western"><surname>Fohner</surname><given-names>AE</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>AE</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>TA</given-names></name><name name-style="western"><surname>Veenstra</surname><given-names>DL</given-names></name></person-group> (<year>2019</year>) <article-title><italic>VKORC1</italic> and novel <italic>CYP2C9</italic> variation predict warfarin response in Alaska native and American indian people.</article-title><source>Clinical and Translational Science</source><volume>12</volume>(<issue>3</issue>): <fpage>312</fpage>–<lpage>320</lpage>. <ext-link xlink:href="10.1111/cts.12611" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/cts.12611</ext-link></mixed-citation>
      </ref>
      <ref id="B43">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Hernández</surname><given-names>l</given-names></name><name name-style="western"><surname>Marín</surname><given-names>K</given-names></name></person-group> (<year>2017</year>) <article-title>Interacciones medicamentosas de los anticonvulsivantes de primera línea con antipsicóticos y/o antidepresivos.</article-title><source>Revista Repertorio de Medicina y Cirugía</source><volume>26</volume>(<issue>2</issue>): <fpage>78</fpage>–<lpage>84</lpage>. <ext-link xlink:href="10.1016/j.reper.2017.05.005" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.reper.2017.05.005</ext-link></mixed-citation>
      </ref>
      <ref id="B44">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Hikino</surname><given-names>K</given-names></name><name name-style="western"><surname>Ozeki</surname><given-names>T</given-names></name><name name-style="western"><surname>Koido</surname><given-names>M</given-names></name><name name-style="western"><surname>Chikashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kamatani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mizukawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shiohara</surname><given-names>T</given-names></name><name name-style="western"><surname>Tohyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Azukizawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Aihara</surname><given-names>M</given-names></name><name name-style="western"><surname>Nihara</surname><given-names>H</given-names></name><name name-style="western"><surname>Morita</surname><given-names>E</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>M</given-names></name><name name-style="western"><surname>Mushiroda</surname><given-names>T</given-names></name></person-group> (<year>2020</year>) <article-title><italic>HLA-B*51:01</italic> and <italic>CYP2C9*3</italic> are risk factors for phenytoin-induced eruption in the japanese population: Analysis of data from the biobank Japan project.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>107</volume>(<issue>5</issue>): <fpage>1170</fpage>–<lpage>1178</lpage>. <ext-link xlink:href="10.1002/cpt.1706" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/cpt.1706</ext-link></mixed-citation>
      </ref>
      <ref id="B45">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Hirota</surname><given-names>T</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I</given-names></name></person-group> (<year>2013</year>) <article-title>Impact of genetic polymorphisms in <italic>CYP2C9</italic> and <italic>CYP2C19</italic> on the pharmacokinetics of clinically used drugs.</article-title><source>Drug Metabolism and Pharmacokinetics</source><volume>28</volume>(<issue>1</issue>): <fpage>28</fpage>–<lpage>37</lpage>. <ext-link xlink:href="10.2133/dmpk.DMPK-12-RV-085" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2133/dmpk.DMPK-12-RV-085</ext-link></mixed-citation>
      </ref>
      <ref id="B46">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Iannaccone</surname><given-names>T</given-names></name><name name-style="western"><surname>Sellitto</surname><given-names>C</given-names></name><name name-style="western"><surname>Manzo</surname><given-names>V</given-names></name><name name-style="western"><surname>Colucci</surname><given-names>F</given-names></name><name name-style="western"><surname>Giudice</surname><given-names>V</given-names></name><name name-style="western"><surname>Stefanelli</surname><given-names>B</given-names></name><name name-style="western"><surname>Iuliano</surname><given-names>A</given-names></name><name name-style="western"><surname>Corrivetti</surname><given-names>G</given-names></name><name name-style="western"><surname>Filippelli</surname><given-names>A</given-names></name></person-group> (<year>2021</year>) Pharmacogenetics of carbamazepine and valproate: focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals 14(3): e204. <ext-link xlink:href="10.3390/ph14030204" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/ph14030204</ext-link></mixed-citation>
      </ref>
      <ref id="B47">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Jiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Müller</surname><given-names>M</given-names></name></person-group> (<year>2009</year>) <article-title>Effects of <italic>CYP2C19</italic> and <italic>CYP2C9</italic> genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.</article-title><source>European Journal of Clinical Pharmacology</source><volume>65</volume>(<issue>12</issue>): <fpage>1187</fpage>–<lpage>1193</lpage>. <ext-link xlink:href="10.1007/s00228-009-0712-x" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s00228-009-0712-x</ext-link></mixed-citation>
      </ref>
      <ref id="B48">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Jin</surname><given-names>C</given-names></name><name name-style="western"><surname>Miners</surname><given-names>JO</given-names></name><name name-style="western"><surname>Lillywhite</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Mackenzie</surname><given-names>PI</given-names></name></person-group> (<year>1993</year>) <article-title>Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>264</volume>(<issue>1</issue>): <fpage>475</fpage>–<lpage>479</lpage>.</mixed-citation>
      </ref>
      <ref id="B49">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Johannessen Landmark</surname><given-names>C</given-names></name><name name-style="western"><surname>Johannessen</surname><given-names>SI</given-names></name><name name-style="western"><surname>Patsalos</surname><given-names>PN</given-names></name></person-group> (<year>2020</year>) <article-title>Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects.</article-title><source>Expert Opinion on Drug Metabolism &amp; Toxicology</source><volume>16</volume>(<issue>3</issue>): <fpage>227</fpage>–<lpage>238</lpage>. <ext-link xlink:href="10.1080/17425255.2020.1724956" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1080/17425255.2020.1724956</ext-link></mixed-citation>
      </ref>
      <ref id="B50">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Kanjanasilp</surname><given-names>J</given-names></name><name name-style="western"><surname>Sawangjit</surname><given-names>R</given-names></name><name name-style="western"><surname>Phanthaisong</surname><given-names>S</given-names></name><name name-style="western"><surname>Borihanthanawuth</surname><given-names>W</given-names></name></person-group> (<year>2021</year>) <article-title>A meta-analysis of effects of <italic>CYP2C9</italic> and <italic>CYP2C19</italic> polymorphisms on phenytoin pharmacokinetic parameters.</article-title><source>Pharmacogenomics</source><volume>22</volume>(<issue>10</issue>): <fpage>629</fpage>–<lpage>640</lpage>. <ext-link xlink:href="10.2217/pgs-2020-0151" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2217/pgs-2020-0151</ext-link></mixed-citation>
      </ref>
      <ref id="B51">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Karnes</surname><given-names>JH</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>AE</given-names></name><name name-style="western"><surname>Somogyi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Huddart</surname><given-names>R</given-names></name><name name-style="western"><surname>Fohner</surname><given-names>AE</given-names></name><name name-style="western"><surname>Formea</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MTM</given-names></name><name name-style="western"><surname>Llerena</surname><given-names>A</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>MW</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Mintzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name><name name-style="western"><surname>Caudle</surname><given-names>KE</given-names></name><name name-style="western"><surname>Callaghan</surname><given-names>JT</given-names></name></person-group> (<year>2021</year>) <article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <italic>CYP2C9</italic> and <italic>HLA-B</italic> genotypes and phenytoin dosing: 2020 Update.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>109</volume>(<issue>2</issue>): <fpage>302</fpage>–<lpage>309</lpage>. <ext-link xlink:href="10.1002/cpt.2008" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/cpt.2008</ext-link></mixed-citation>
      </ref>
      <ref id="B52">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Kwan</surname><given-names>P</given-names></name><name name-style="western"><surname>Arzimanoglou</surname><given-names>A</given-names></name><name name-style="western"><surname>Berg</surname><given-names>AT</given-names></name><name name-style="western"><surname>Brodie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>WA</given-names></name><name name-style="western"><surname>Mathern</surname><given-names>G</given-names></name><name name-style="western"><surname>Moshé</surname><given-names>SL</given-names></name><name name-style="western"><surname>Perucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Wiebe</surname><given-names>S</given-names></name><name name-style="western"><surname>French</surname><given-names>J</given-names></name></person-group> (<year>2010</year>) <article-title>Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.</article-title><source>Epilepsia</source><volume>51</volume>(<issue>6</issue>): <fpage>1069</fpage>–<lpage>1077</lpage>. <ext-link xlink:href="10.1111/j.1528-1167.2009.02397.x" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/j.1528-1167.2009.02397.x</ext-link></mixed-citation>
      </ref>
      <ref id="B53">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name></person-group> (<year>2013</year>) Clinical application of <italic>CYP2C19</italic> pharmacogenetics Toward More Personalized Medicine. Frontiers in Genetics 3: e318. <ext-link xlink:href="10.3389/fgene.2012.00318" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3389/fgene.2012.00318</ext-link></mixed-citation>
      </ref>
      <ref id="B54">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Liao</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ai</surname><given-names>CZ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name></person-group> (<year>2018</year>) <article-title>The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis.</article-title><source>International Journal of Clinical Pharmacology and Therapeutics</source><volume>56</volume>(<issue>7</issue>): <fpage>337</fpage>–<lpage>346</lpage>. <ext-link xlink:href="10.5414/CP203083" ext-link-type="doi" xlink:type="simple">https://doi.org/10.5414/CP203083</ext-link></mixed-citation>
      </ref>
      <ref id="B55">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><name name-style="western"><surname>Ren</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group> (<year>2021</year>) Therapeutic drug monitoring of valproic acid using a dried plasma spot sampling device. Journal of Mass Spectrometry 56(4): e4603. <ext-link xlink:href="10.1002/jms.4603" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/jms.4603</ext-link></mixed-citation>
      </ref>
      <ref id="B56">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Lim</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Cha</surname><given-names>EY</given-names></name><name name-style="western"><surname>Jung</surname><given-names>HE</given-names></name><name name-style="western"><surname>Jung</surname><given-names>HE</given-names></name><name name-style="western"><surname>Ghim</surname><given-names>JL</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>EY</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JG</given-names></name></person-group> (<year>2014</year>) <article-title>Genetic polymorphisms of <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, <italic>CYP2D6</italic>, <italic>CYP3A4</italic>, and <italic>CYP3A5</italic> in Vietnamese-Koreans.</article-title><source>Translational and Clinical Pharmacology</source><volume>22</volume>(<issue>2</issue>): <fpage>70</fpage>–<lpage>77</lpage>. <ext-link xlink:href="10.12793/tcp.2014.22.2.70" ext-link-type="doi" xlink:type="simple">https://doi.org/10.12793/tcp.2014.22.2.70</ext-link></mixed-citation>
      </ref>
      <ref id="B57">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>López-García</surname><given-names>MA</given-names></name><name name-style="western"><surname>Feria-Romero</surname><given-names>IA</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>H</given-names></name><name name-style="western"><surname>Escalante-Santiago</surname><given-names>D</given-names></name><name name-style="western"><surname>Grijalva</surname><given-names>I</given-names></name><name name-style="western"><surname>Orozco-Suarez</surname><given-names>S</given-names></name></person-group> (<year>2014</year>) <article-title>Genetic polymorphisms associated with antiepileptic metabolism.</article-title><source>Frontiers in Bioscience</source><volume>6</volume>(<issue>2</issue>): <fpage>377</fpage>–<lpage>386</lpage>. <ext-link xlink:href="10.2741/e713" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2741/e713</ext-link></mixed-citation>
      </ref>
      <ref id="B58">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>López-García</surname><given-names>MA</given-names></name><name name-style="western"><surname>Feria-Romero</surname><given-names>IA</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>H</given-names></name><name name-style="western"><surname>Rayo-Mares</surname><given-names>D</given-names></name><name name-style="western"><surname>Fagiolino</surname><given-names>P</given-names></name><name name-style="western"><surname>Vázquez</surname><given-names>M</given-names></name><name name-style="western"><surname>Escamilla-Núñez</surname><given-names>C</given-names></name><name name-style="western"><surname>Grijalva</surname><given-names>I</given-names></name><name name-style="western"><surname>Escalante-Santiago</surname><given-names>D</given-names></name><name name-style="western"><surname>Orozco-Suarez</surname><given-names>S</given-names></name></person-group> (<year>2017</year>) <article-title>Influence of genetic variants of <italic>CYP2D6</italic>, <italic>CYP2C9</italic>, <italic>CYP2C19</italic> and <italic>CYP3A4</italic> on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.</article-title><source>Pharmacological Reports</source><volume>69</volume>(<issue>3</issue>): <fpage>504</fpage>–<lpage>511</lpage>. <ext-link xlink:href="10.1016/j.pharep.2017.01.007" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.pharep.2017.01.007</ext-link></mixed-citation>
      </ref>
      <ref id="B59">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Makowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Smolarz</surname><given-names>B</given-names></name><name name-style="western"><surname>Bryś</surname><given-names>M</given-names></name><name name-style="western"><surname>Forma</surname><given-names>E</given-names></name><name name-style="western"><surname>Romanowicz</surname><given-names>H</given-names></name></person-group> (<year>2021</year>) <article-title>An association between the <italic>rs1799853</italic> and <italic>rs1057910</italic> polymorphisms of <italic>CYP2C9</italic>, the <italic>rs4244285</italic> polymorphism of <italic>CYP2C19</italic> and the prevalence rates of drug-resistant epilepsy in children.</article-title><source>International Journal of Neuroscience</source><volume>131</volume>(<issue>12</issue>): <fpage>1147</fpage>–<lpage>1154</lpage>. <ext-link xlink:href="10.1080/00207454.2020.1781110" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1080/00207454.2020.1781110</ext-link></mixed-citation>
      </ref>
      <ref id="B60">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Maqbool</surname><given-names>H</given-names></name><name name-style="western"><surname>Saleem</surname><given-names>T</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>N</given-names></name><name name-style="western"><surname>Ashfaq</surname><given-names>A</given-names></name></person-group> (<year>2022</year>) Genetic analysis of <italic>CYP2C9</italic> with reference to drug response in epilepsy patients of Pakistan. Genetics Research: e1451007. <ext-link xlink:href="10.1155/2022/1451007" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1155/2022/1451007</ext-link></mixed-citation>
      </ref>
      <ref id="B61">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Maruf</surname><given-names>AA</given-names></name><name name-style="western"><surname>Greenslade</surname><given-names>A</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>PD</given-names></name><name name-style="western"><surname>Bousman</surname><given-names>C</given-names></name></person-group> (<year>2019</year>) <article-title>Antidepressant pharmacogenetics in children and young adults: A systematic review.</article-title><source>Journal of Affective Disorders</source><volume>254</volume>: <fpage>98</fpage>–<lpage>108</lpage>. <ext-link xlink:href="10.1016/j.jad.2019.05.025" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.jad.2019.05.025</ext-link></mixed-citation>
      </ref>
      <ref id="B62">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Milosheska</surname><given-names>D</given-names></name><name name-style="western"><surname>Grabnar</surname><given-names>I</given-names></name><name name-style="western"><surname>Vovk</surname><given-names>T</given-names></name></person-group> (<year>2015</year>) <article-title>Dried blood spots for monitoring and individualization of antiepileptic drug treatment.</article-title><source>European Journal of Pharmaceutical Sciences</source><volume>75</volume>: <fpage>25</fpage>–<lpage>39</lpage>. <ext-link xlink:href="10.1016/j.ejps.2015.04.008" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.ejps.2015.04.008</ext-link></mixed-citation>
      </ref>
      <ref id="B63">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Mirzaev</surname><given-names>KB</given-names></name><name name-style="western"><surname>Zelenskaya</surname><given-names>EM</given-names></name><name name-style="western"><surname>Barbarash</surname><given-names>OL</given-names></name><name name-style="western"><surname>Ganyukov</surname><given-names>VI</given-names></name><name name-style="western"><surname>Apartsin</surname><given-names>KA</given-names></name><name name-style="western"><surname>Saraeva</surname><given-names>NO</given-names></name><name name-style="western"><surname>Nikolaev</surname><given-names>KY</given-names></name><name name-style="western"><surname>Ryzhikova</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lifshits</surname><given-names>GI</given-names></name><name name-style="western"><surname>Sychev</surname><given-names>DA</given-names></name></person-group> (<year>2017</year>) <article-title><italic>CYP2C19</italic> polymorphism frequency in Russian patients in central Russia and Siberia with acute coronary syndrome.</article-title><source>Pharmacogenomics and Personalized Medicine</source><volume>10</volume>: <fpage>107</fpage>–<lpage>114</lpage>. <ext-link xlink:href="10.2147/PGPM.S126305" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2147/PGPM.S126305</ext-link></mixed-citation>
      </ref>
      <ref id="B64">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Mittal</surname><given-names>B</given-names></name><name name-style="western"><surname>Tulsyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>RD</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>G</given-names></name></person-group> (<year>2015</year>) <article-title>Cytochrome P450 in cancer susceptibility and treatment.</article-title><source>Advances in Clinical Chemistry</source><volume>71</volume>: <fpage>77</fpage>–<lpage>139</lpage>. <ext-link xlink:href="10.1016/bs.acc.2015.06.003" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/bs.acc.2015.06.003</ext-link></mixed-citation>
      </ref>
      <ref id="B65">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Monostory</surname><given-names>K</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>A</given-names></name><name name-style="western"><surname>Tóth</surname><given-names>K</given-names></name><name name-style="western"><surname>Bűdi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Déri</surname><given-names>M</given-names></name><name name-style="western"><surname>Csukly</surname><given-names>G</given-names></name></person-group> (<year>2019</year>) <article-title>Relevance of <italic>CYP2C9</italic> function in valproate therapy.</article-title><source>Current Neuropharmacology</source><volume>17</volume>(<issue>1</issue>): <fpage>99</fpage>–<lpage>106</lpage>. <ext-link xlink:href="10.2174/1570159X15666171109143654" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2174/1570159X15666171109143654</ext-link></mixed-citation>
      </ref>
      <ref id="B66">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Moshe</surname><given-names>SL</given-names></name><name name-style="western"><surname>Perucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Ryvlin</surname><given-names>P</given-names></name><name name-style="western"><surname>Tomson</surname><given-names>T</given-names></name></person-group> (<year>2015</year>) <article-title>Epilepsy: new advances.</article-title><source>Lancet</source><volume>385</volume>(<issue>9971</issue>): <fpage>884</fpage>–<lpage>898</lpage>. <ext-link xlink:href="10.1016/S0140-6736(14)60456-6" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/S0140-6736(14)60456-6</ext-link></mixed-citation>
      </ref>
      <ref id="B67">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Mukai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Narita</surname><given-names>M</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>E</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Toda</surname><given-names>T</given-names></name><name name-style="western"><surname>Rane</surname><given-names>A</given-names></name><name name-style="western"><surname>Inotsume</surname><given-names>N</given-names></name></person-group> (<year>2017</year>) <article-title>Co-administration of fluvastatin and <italic>CYP3A4</italic> and <italic>cyp2c8</italic> inhibitors may increase the exposure to fluvastatin in carriers of <italic>CYP2C9</italic> genetic variants.</article-title><source>Biological and Pharmaceutical Bulletin</source><volume>40</volume>(<issue>7</issue>): <fpage>1078</fpage>–<lpage>1085</lpage>. <ext-link xlink:href="10.1248/bpb.b17-00150" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1248/bpb.b17-00150</ext-link></mixed-citation>
      </ref>
      <ref id="B68">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Orsini</surname><given-names>A</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>M</given-names></name><name name-style="western"><surname>Perna</surname><given-names>D</given-names></name><name name-style="western"><surname>Bonuccelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Peroni</surname><given-names>D</given-names></name><name name-style="western"><surname>Striano</surname><given-names>P</given-names></name></person-group> (<year>2018</year>) <article-title>Personalized medicine in epilepsy patients.</article-title><source>Journal of Translational Genetics and Genomics</source><volume>2</volume>: <fpage>1</fpage>–<lpage>18</lpage>. <ext-link xlink:href="10.20517/jtgg.2018.14" ext-link-type="doi" xlink:type="simple">https://doi.org/10.20517/jtgg.2018.14</ext-link></mixed-citation>
      </ref>
      <ref id="B69">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ortega-Vázquez</surname><given-names>A</given-names></name><name name-style="western"><surname>Dorado</surname><given-names>P</given-names></name><name name-style="western"><surname>Fricke-Galindo</surname><given-names>I</given-names></name><name name-style="western"><surname>Jung-Cook</surname><given-names>H</given-names></name><name name-style="western"><surname>Monroy-Jaramillo</surname><given-names>N</given-names></name><name name-style="western"><surname>Martínez-Juárez</surname><given-names>IE</given-names></name><name name-style="western"><surname>Familiar-López</surname><given-names>I</given-names></name><name name-style="western"><surname>Peñas-Lledó</surname><given-names>E</given-names></name><name name-style="western"><surname>LLerena</surname><given-names>A</given-names></name><name name-style="western"><surname>López-López</surname><given-names>M</given-names></name></person-group> (<year>2016</year>) <article-title><italic>CYP2C9</italic>, <italic>CYP2C19</italic>, <italic>ABCB1</italic> genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.</article-title><source>The Pharmacogenomics Journal</source><volume>16</volume>: <fpage>286</fpage>–<lpage>292</lpage>. <ext-link xlink:href="10.1038/tpj.2015.45" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/tpj.2015.45</ext-link></mixed-citation>
      </ref>
      <ref id="B70">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Pinto</surname><given-names>N</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>ME</given-names></name></person-group> (<year>2011</year>) <article-title>Clinically relevant genetic variations in drug metabolizing enzymes.</article-title><source>Current Drug Metabolism</source><volume>12</volume>(<issue>5</issue>): <fpage>487</fpage>–<lpage>497</lpage>. <ext-link xlink:href="10.2174/138920011795495321" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2174/138920011795495321</ext-link></mixed-citation>
      </ref>
      <ref id="B71">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Saeed</surname><given-names>LH</given-names></name><name name-style="western"><surname>Mayet</surname><given-names>AY</given-names></name></person-group> (<year>2013</year>) <article-title>Genotype-phenotype analysis of <italic>CYP2C19</italic> in healthy saudi individuals and its potential clinical implication in drug therapy.</article-title><source>International Journal of Medical Sciences</source><volume>10</volume>(<issue>11</issue>): <fpage>1497</fpage>–<lpage>1502</lpage>. <ext-link xlink:href="10.7150/ijms.6795" ext-link-type="doi" xlink:type="simple">https://doi.org/10.7150/ijms.6795</ext-link></mixed-citation>
      </ref>
      <ref id="B72">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Saldaña-Cruz</surname><given-names>A</given-names></name><name name-style="western"><surname>Sánchez-Corona</surname><given-names>J</given-names></name><name name-style="western"><surname>Márquez-de Santiago</surname><given-names>D</given-names></name><name name-style="western"><surname>García-Zapién</surname><given-names>A</given-names></name><name name-style="western"><surname>Flores-Martínez</surname><given-names>S</given-names></name></person-group> (<year>2013</year>) <article-title>Farmacogenética y metabolismo de fármacos antiepilépticos: implicación de variantes genéticas en citocromos P450.</article-title><source>Revue Neurologique</source><volume>56</volume>(<issue>09</issue>): <fpage>471</fpage>–<lpage>479</lpage>. <ext-link xlink:href="10.33588/rn.5609.2013131" ext-link-type="doi" xlink:type="simple">https://doi.org/10.33588/rn.5609.2013131</ext-link></mixed-citation>
      </ref>
      <ref id="B73">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Scott</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sangkuhl</surname><given-names>K</given-names></name><name name-style="western"><surname>Stein</surname><given-names>CM</given-names></name><name name-style="western"><surname>J-S</surname><given-names>Hulot</given-names></name><name name-style="western"><surname>Mega</surname><given-names>JL</given-names></name><name name-style="western"><surname>Roden</surname><given-names>DM</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name><name name-style="western"><surname>Sabatine</surname><given-names>MS</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Shuldiner</surname><given-names>AR</given-names></name></person-group> (<year>2013</year>) <article-title>Clinical pharmacogenetics implementation consortium guidelines for <italic>CYP2C19</italic> genotype and clopidogrel therapy: 2013 update.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>94</volume>(<issue>3</issue>): <fpage>317</fpage>–<lpage>323</lpage>. <ext-link xlink:href="10.1038/clpt.2013.105" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/clpt.2013.105</ext-link></mixed-citation>
      </ref>
      <ref id="B74">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Scott</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sangkuhl</surname><given-names>K</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>EE</given-names></name><name name-style="western"><surname>Stein</surname><given-names>CM</given-names></name><name name-style="western"><surname>Hulot</surname><given-names>JS</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Roden</surname><given-names>DM</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name><name name-style="western"><surname>Shuldiner</surname><given-names>AR</given-names></name></person-group> (<year>2011</year>) <article-title>Clinical pharmacogenetics implementation consortium clinical pharmacogenetics implementation consortium guidelines for cytochrome <italic>P450–2C19</italic> (<italic>CYP2C19</italic>) genotype and clopidogrel therapy.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>90</volume>(<issue>2</issue>): <fpage>328</fpage>–<lpage>332</lpage>. <ext-link xlink:href="10.1038/clpt.2011.132" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/clpt.2011.132</ext-link></mixed-citation>
      </ref>
      <ref id="B75">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Seven</surname><given-names>M</given-names></name><name name-style="western"><surname>Batar</surname><given-names>B</given-names></name><name name-style="western"><surname>Unal</surname><given-names>S</given-names></name><name name-style="western"><surname>Yesil</surname><given-names>G</given-names></name><name name-style="western"><surname>Yuksel</surname><given-names>A</given-names></name><name name-style="western"><surname>Guven</surname><given-names>M</given-names></name></person-group> (<year>2014</year>) <article-title>The effect of genetic polymorphisms of cytochrome <italic>P450 CYP2C9</italic>, <italic>CYP2C19</italic>, and <italic>CYP2D6</italic> on drug-resistant epilepsy in Turkish children.</article-title><source>Molecular Diagnosis &amp; Therapy</source><volume>18</volume>(<issue>2</issue>): <fpage>229</fpage>–<lpage>236</lpage>. <ext-link xlink:href="10.1007/s40291-013-0078-8" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s40291-013-0078-8</ext-link></mixed-citation>
      </ref>
      <ref id="B76">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Shnayder</surname><given-names>NA</given-names></name><name name-style="western"><surname>Grechkina</surname><given-names>VV</given-names></name><name name-style="western"><surname>Khasanova</surname><given-names>AK</given-names></name><name name-style="western"><surname>Bochanova</surname><given-names>EN</given-names></name><name name-style="western"><surname>Dontceva</surname><given-names>EA</given-names></name><name name-style="western"><surname>Petrova</surname><given-names>MM</given-names></name><name name-style="western"><surname>Asadullin</surname><given-names>AR</given-names></name><name name-style="western"><surname>Shipulin</surname><given-names>GA</given-names></name><name name-style="western"><surname>Altynbekov</surname><given-names>KS</given-names></name><name name-style="western"><surname>Al-Zamil</surname><given-names>M</given-names></name><name name-style="western"><surname>Nasyrova</surname><given-names>RF</given-names></name></person-group> (<year>2023</year>) Therapeutic and toxic effects of valproic acid metabolites. Metabolites 13(1): e134. <ext-link xlink:href="10.3390/metabo13010134" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/metabo13010134</ext-link></mixed-citation>
      </ref>
      <ref id="B77">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Silvado</surname><given-names>CE</given-names></name><name name-style="western"><surname>Terra</surname><given-names>VC</given-names></name><name name-style="western"><surname>Twardowschy</surname><given-names>CA</given-names></name></person-group> (<year>2018</year>) <article-title><italic>CYP2C9</italic> polymorphisms in epilepsy: influence on phenytoin treatment.</article-title><source>Pharmacogenomics and Personalized Medicine</source><volume>11</volume>: <fpage>51</fpage>–<lpage>58</lpage>. <ext-link xlink:href="10.2147/PGPM.S108113" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2147/PGPM.S108113</ext-link></mixed-citation>
      </ref>
      <ref id="B78">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Sillanpaa</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>D</given-names></name></person-group> (<year>2006</year>) <article-title>Natural history of treated childhood-onset epilepsy: prospective, longterm population-based study.</article-title><source>Brain</source><volume>129</volume>: <fpage>617</fpage>–<lpage>624</lpage>. <ext-link xlink:href="10.1093/brain/awh726" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1093/brain/awh726</ext-link></mixed-citation>
      </ref>
      <ref id="B79">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Sim</surname><given-names>SC</given-names></name><name name-style="western"><surname>Risinger</surname><given-names>C</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>ML</given-names></name><name name-style="western"><surname>Aklillu</surname><given-names>E</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>M</given-names></name><name name-style="western"><surname>Bertilsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group> (<year>2006</year>) <article-title>A common novel <italic>CYP2C19</italic> gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>79</volume>(<issue>1</issue>): <fpage>103</fpage>–<lpage>113</lpage>. <ext-link xlink:href="10.1016/j.clpt.2005.10.002" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.clpt.2005.10.002</ext-link></mixed-citation>
      </ref>
      <ref id="B80">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Sisodiya</surname><given-names>SM</given-names></name><name name-style="western"><surname>Marini</surname><given-names>C</given-names></name></person-group> (<year>2009</year>) <article-title>Genetics of antiepileptic drug resistance.</article-title><source>Current Opinion in Neurology</source><volume>22</volume>(<issue>2</issue>): <fpage>150</fpage>–<lpage>156</lpage>. <ext-link xlink:href="10.1097/WCO.0b013e32832923ec" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1097/WCO.0b013e32832923ec</ext-link></mixed-citation>
      </ref>
      <ref id="B81">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Skadrić</surname><given-names>I</given-names></name><name name-style="western"><surname>Stojković</surname><given-names>O</given-names></name></person-group> (<year>2020</year>) <article-title>Defining screening panel of functional variants of <italic>CYP1A1</italic>, <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, <italic>CYP2D6</italic>, and <italic>CYP3A4</italic> genes in Serbian population.</article-title><source>International Journal of Legal Medicine</source><volume>134</volume>(<issue>2</issue>): <fpage>433</fpage>–<lpage>439</lpage>. <ext-link xlink:href="10.1007/s00414-019-02234-7" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s00414-019-02234-7</ext-link></mixed-citation>
      </ref>
      <ref id="B82">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Smolarz</surname><given-names>B</given-names></name><name name-style="western"><surname>Makowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Romanowicz</surname><given-names>H</given-names></name></person-group> (<year>2021</year>) Pharmacogenetics of drug-resistant epilepsy (review of literature). International Journal of Molecular Sciences 22(21): e11696. <ext-link xlink:href="10.3390/ijms222111696" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3390/ijms222111696</ext-link></mixed-citation>
      </ref>
      <ref id="B83">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Song</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Mao</surname><given-names>P</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group> (<year>2022</year>) <article-title>Impact of <italic>CYP2C19</italic> and <italic>CYP2C9</italic> gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.</article-title><source>European Journal of Hospital Pharmacy (EJHP)</source><volume>29</volume>(<issue>4</issue>): <fpage>198</fpage>–<lpage>201</lpage>. <ext-link xlink:href="10.1136/ejhpharm-2020-002367" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1136/ejhpharm-2020-002367</ext-link></mixed-citation>
      </ref>
      <ref id="B84">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Staines</surname><given-names>AG</given-names></name><name name-style="western"><surname>Coughtrie</surname><given-names>MW</given-names></name><name name-style="western"><surname>Burchell</surname><given-names>B</given-names></name></person-group> (<year>2004</year>) <article-title>N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7.</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>311</volume>(<issue>3</issue>): <fpage>1131</fpage>–<lpage>1137</lpage>. <ext-link xlink:href="10.1124/jpet.104.073114" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1124/jpet.104.073114</ext-link></mixed-citation>
      </ref>
      <ref id="B85">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Su</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CB</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CW</given-names></name><name name-style="western"><surname>Wen-Lang</surname><given-names>A Lu</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>LYR</given-names></name><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ueta</surname><given-names>M</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>S</given-names></name><name name-style="western"><surname>Sukasem</surname><given-names>C</given-names></name><name name-style="western"><surname>Yampayón</surname><given-names>K</given-names></name><name name-style="western"><surname>Kijsanayotin</surname><given-names>P</given-names></name><name name-style="western"><surname>Nakkam</surname><given-names>N</given-names></name><name name-style="western"><surname>Saksit</surname><given-names>N</given-names></name><name name-style="western"><surname>Tassaneeyakul</surname><given-names>W</given-names></name><name name-style="western"><surname>Aihara</surname><given-names>M</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YJr</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Hung</surname><given-names>SI</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WH</given-names></name></person-group> (<year>2019</year>) <article-title>HLA alleles and <italic>CYP2C9*3</italic> as predictors of phenytoin hypersensitivity in east Asians.</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>105</volume>(<issue>2</issue>): <fpage>476</fpage>–<lpage>485</lpage>. <ext-link xlink:href="10.1002/cpt.1190" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/cpt.1190</ext-link></mixed-citation>
      </ref>
      <ref id="B86">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Sukasem</surname><given-names>C</given-names></name><name name-style="western"><surname>Sririttha</surname><given-names>S</given-names></name><name name-style="western"><surname>de Therdpong</surname><given-names>T</given-names></name><name name-style="western"><surname>Klaewsongkram</surname><given-names>J</given-names></name><name name-style="western"><surname>Rerkpattanapipat</surname><given-names>T</given-names></name><name name-style="western"><surname>Puangpetch</surname><given-names>A</given-names></name><name name-style="western"><surname>Boongird</surname><given-names>A</given-names></name><name name-style="western"><surname>Chulavatnatol</surname><given-names>S</given-names></name></person-group> (<year>2020</year>) <article-title>Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population.</article-title><source>Pharmacoepidemiology and Drug Safety</source><volume>29</volume>(<issue>5</issue>): <fpage>565</fpage>–<lpage>574</lpage>. <ext-link xlink:href="10.1002/pds.4979" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1002/pds.4979</ext-link></mixed-citation>
      </ref>
      <ref id="B87">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Suvichapanich</surname><given-names>S</given-names></name><name name-style="western"><surname>Jittikoon</surname><given-names>J</given-names></name><name name-style="western"><surname>Wichukchinda</surname><given-names>N</given-names></name><name name-style="western"><surname>Kamchaisatian</surname><given-names>W</given-names></name><name name-style="western"><surname>Visudtibhan</surname><given-names>A</given-names></name><name name-style="western"><surname>Benjapopitak</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakornchai</surname><given-names>S</given-names></name><name name-style="western"><surname>Manuyakorn</surname><given-names>W</given-names></name><name name-style="western"><surname>Mahasirimongkol</surname><given-names>S</given-names></name></person-group> (<year>2015</year>) <article-title>Association analysis of <italic>CYP2C9*3</italic> and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.</article-title><source>Journal of Human Genetics</source><volume>60</volume>(<issue>8</issue>): <fpage>413</fpage>–<lpage>417</lpage>. <ext-link xlink:href="10.1038/jhg.2015.47" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1038/jhg.2015.47</ext-link></mixed-citation>
      </ref>
      <ref id="B88">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Tabari</surname><given-names>RG</given-names></name><name name-style="western"><surname>Marjani</surname><given-names>A</given-names></name><name name-style="western"><surname>Ataby</surname><given-names>OA</given-names></name><name name-style="western"><surname>Mansourian</surname><given-names>AR</given-names></name><name name-style="western"><surname>Samai</surname><given-names>NM</given-names></name></person-group> (<year>2013</year>) <article-title>Genetic polymorphism of cytochrome p450 (2C19) enzyme in Iranian Turkman ethnic group.</article-title><source>Oman Medical Journal</source><volume>28</volume>(<issue>4</issue>): <fpage>237</fpage>–<lpage>244</lpage>. <ext-link xlink:href="10.5001/omj.2013.69" ext-link-type="doi" xlink:type="simple">https://doi.org/10.5001/omj.2013.69</ext-link></mixed-citation>
      </ref>
      <ref id="B89">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JT</given-names></name><name name-style="western"><surname>Sun</surname><given-names>YP</given-names></name><name name-style="western"><surname>Ou</surname><given-names>JR</given-names></name><name name-style="western"><surname>Song</surname><given-names>JH</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name></person-group> (<year>2010</year>) <article-title>The influence of cytochrome oxidase <italic>CYP2A6</italic>, <italic>CYP2B6</italic>, and <italic>CYP2C9</italic> polymorphisms on the plasma concentrations of valproic acid in epileptic patients.</article-title><source>Clinical Neurology and Neurosurgery</source><volume>112</volume>(<issue>4</issue>): <fpage>320</fpage>–<lpage>323</lpage>. <ext-link xlink:href="10.1016/j.clineuro.2010.01.002" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.clineuro.2010.01.002</ext-link></mixed-citation>
      </ref>
      <ref id="B90">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Thaker</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Gandhe</surname><given-names>PP</given-names></name><name name-style="western"><surname>Godbole</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Bendkhale</surname><given-names>SR</given-names></name><name name-style="western"><surname>Mali</surname><given-names>NB</given-names></name><name name-style="western"><surname>Thatte</surname><given-names>UM</given-names></name><name name-style="western"><surname>Gogtay</surname><given-names>NJ</given-names></name></person-group> (<year>2017</year>) <article-title>A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy.</article-title><source>Journal of Ayurveda and Integrative Medicine</source><volume>8</volume>(<issue>1</issue>): <fpage>37</fpage>–<lpage>41</lpage>. <ext-link xlink:href="10.1016/j.jaim.2016.12.001" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.jaim.2016.12.001</ext-link></mixed-citation>
      </ref>
      <ref id="B91">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Thong</surname><given-names>BY</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>M</given-names></name><name name-style="western"><surname>Kang</surname><given-names>HR</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YS</given-names></name><name name-style="western"><surname>Li</surname><given-names>PH</given-names></name><name name-style="western"><surname>Tang</surname><given-names>MM</given-names></name><name name-style="western"><surname>Yun</surname><given-names>J</given-names></name><name name-style="western"><surname>Fok</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BK</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>M</given-names></name><name name-style="western"><surname>Rengganis</surname><given-names>I</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>YG</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WH</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rerkpattanapipat</surname><given-names>T</given-names></name><name name-style="western"><surname>Kamchaisatian</surname><given-names>W</given-names></name><name name-style="western"><surname>Leung</surname><given-names>TF</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Latiff</surname><given-names>AHA</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Thien</surname><given-names>F</given-names></name><name name-style="western"><surname>Castells</surname><given-names>MC</given-names></name><name name-style="western"><surname>Demoly</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Pawankar</surname><given-names>R</given-names></name></person-group> (<year>2020</year>) Drug hypersensitivity reactions in Asia: regional issues and challenges. Asia Pacific Allergy 10(1): e8. <ext-link xlink:href="10.5415/apallergy.2020.10.e8" ext-link-type="doi" xlink:type="simple">https://doi.org/10.5415/apallergy.2020.10.e8</ext-link></mixed-citation>
      </ref>
      <ref id="B92">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>van der Weide</surname><given-names>J</given-names></name><name name-style="western"><surname>Steijns</surname><given-names>LS</given-names></name><name name-style="western"><surname>van Weelden</surname><given-names>MJ</given-names></name><name name-style="western"><surname>de Haan</surname><given-names>K</given-names></name></person-group> (<year>2001</year>) <article-title>The effect of genetic polymorphism of cytochrome P450 <italic>CYP2C9</italic> on phenytoin dose requirement.</article-title><source>Pharmacogenetics</source><volume>11</volume>(<issue>4</issue>): <fpage>287</fpage>–<lpage>291</lpage>. <ext-link xlink:href="10.1097/00008571-200106000-00002" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1097/00008571-200106000-00002</ext-link></mixed-citation>
      </ref>
      <ref id="B93">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Vargas</surname><given-names>R</given-names></name><name name-style="western"><surname>Cobar</surname><given-names>O</given-names></name></person-group> (<year>2021</year>) <article-title><italic>CYP450</italic> y farmacogenética en Guatemala. Revisión narrativa.</article-title><source>Ciencia, Tecnología y Salud – USAC</source><volume>8</volume>(<issue>2</issue>): <fpage>211</fpage>–<lpage>219</lpage>. <ext-link xlink:href="10.36829/63CTS.v8i2.947" ext-link-type="doi" xlink:type="simple">https://doi.org/10.36829/63CTS.v8i2.947</ext-link></mixed-citation>
      </ref>
      <ref id="B94">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Wallenburg</surname><given-names>E</given-names></name><name name-style="western"><surname>Klok</surname><given-names>B</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>K</given-names></name><name name-style="western"><surname>de Maat</surname><given-names>M</given-names></name><name name-style="western"><surname>van Erp</surname><given-names>N</given-names></name><name name-style="western"><surname>Stalpers-Konijnenburg</surname><given-names>S</given-names></name><name name-style="western"><surname>Essink</surname><given-names>G</given-names></name><name name-style="western"><surname>van Luin</surname><given-names>M</given-names></name></person-group> (<year>2017</year>) <article-title>Monitoring protein-unbound valproic acid serum concentrations in clinical practice.</article-title><source>Therapeutic Drug Monitoring</source><volume>39</volume>(<issue>3</issue>): <fpage>269</fpage>–<lpage>272</lpage>. <ext-link xlink:href="10.1097/FTD.0000000000000405" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1097/FTD.0000000000000405</ext-link></mixed-citation>
      </ref>
      <ref id="B95">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bradbury</surname><given-names>JA</given-names></name><name name-style="western"><surname>Graves</surname><given-names>JP</given-names></name><name name-style="western"><surname>Foley</surname><given-names>J</given-names></name><name name-style="western"><surname>Blaisdell</surname><given-names>JA</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>JA</given-names></name><name name-style="western"><surname>Zeldin</surname><given-names>DC</given-names></name></person-group> (<year>2004</year>) <article-title>Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities.</article-title><source>Molecular Pharmacology</source><volume>65</volume>(<issue>5</issue>): <fpage>1148</fpage>–<lpage>1158</lpage>. <ext-link xlink:href="10.1124/mol.65.5.1148" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1124/mol.65.5.1148</ext-link></mixed-citation>
      </ref>
      <ref id="B96">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>An</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Bian</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name></person-group> (<year>2011</year>) <article-title>Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of <italic>CYP2C19</italic> on S-mephenytoin 4’-hydroxylation and omeprazole 5’-hydroxylation.</article-title><source>Drug Metabolism &amp; Disposition</source><volume>39</volume>(<issue>5</issue>): <fpage>830</fpage>–<lpage>837</lpage>. <ext-link xlink:href="10.1124/dmd.110.037549" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1124/dmd.110.037549</ext-link></mixed-citation>
      </ref>
      <ref id="B97">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name></person-group> (<year>2018</year>) <article-title>Association of <italic>CYP2C9*3</italic> with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis.</article-title><source>Journal of Clinical Pharmacy and Therapeutics</source><volume>43</volume>(<issue>3</issue>): <fpage>408</fpage>–<lpage>413</lpage>. <ext-link xlink:href="10.1111/jcpt.12660" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/jcpt.12660</ext-link></mixed-citation>
      </ref>
      <ref id="B98">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Yampayon</surname><given-names>K</given-names></name><name name-style="western"><surname>Sukasem</surname><given-names>C</given-names></name><name name-style="western"><surname>Limwongse</surname><given-names>C</given-names></name><name name-style="western"><surname>Chinvarun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tempark</surname><given-names>T</given-names></name><name name-style="western"><surname>Rerkpattanapipat</surname><given-names>T</given-names></name><name name-style="western"><surname>Kijsanayotin</surname><given-names>P</given-names></name></person-group> (<year>2017</year>) <article-title>Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.</article-title><source>European Journal of Clinical Pharmacology</source><volume>73</volume>(<issue>7</issue>): <fpage>855</fpage>–<lpage>865</lpage>. <ext-link xlink:href="10.1007/s00228-017-2250-2" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s00228-017-2250-2</ext-link></mixed-citation>
      </ref>
      <ref id="B99">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Yin</surname><given-names>T</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>T</given-names></name></person-group> (<year>2011</year>) <article-title>Pharmacogenomics of clopidogrel: evidence and perspectives.</article-title><source>Thrombosis Research</source><volume>128</volume>(<issue>4</issue>): <fpage>307</fpage>–<lpage>316</lpage>. <ext-link xlink:href="10.1016/j.thromres.2011.04.010" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.thromres.2011.04.010</ext-link></mixed-citation>
      </ref>
      <ref id="B100">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Yoon</surname><given-names>HY</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>MH</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name><name name-style="western"><surname>Han</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gwak</surname><given-names>HS</given-names></name></person-group> (<year>2020</year>) <article-title>Influence of <italic>CYP2C9</italic> and <italic>CYP2A6</italic> on plasma concentrations of valproic acid: a meta-analysis.</article-title><source>European Journal of Clinical Pharmacology</source><volume>76</volume>(<issue>8</issue>): <fpage>1053</fpage>–<lpage>1058</lpage>. <ext-link xlink:href="10.1007/s00228-020-02872-6" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s00228-020-02872-6</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
